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ROLE OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 IN 
TUMORIGENESIS AND CANCER BIOLOGY 
 
Marcus W. Stepp 
June 12th, 2017 
 
Human arylamine N-acetyltransferase 1 (NAT1) is a well-known phase II 
metabolic enzyme that has been associated with carcinogenesis. Its role in the 
biotransformation of aromatic and heterocyclic amine carcinogens has been 
investigated for many years, but more recent investigations focus on a possible 
endogenous role of human NAT1 in cancer initiation and progression. To further 
explore and understand possible endogenous roles for NAT1, we conducted in 
vitro enzymatic reactions, in vivo studies using homozygous high (rapid) or low 
(slow) NAT2 activity congenic F344.WKY rats, and genetically modified human 
breast cancer cell lines. Human NAT1 and rodent NAT2 hydrolyzed acetyl-
coenzyme A (AcCoA) in a folate-dependent manner. This hydrolytic function of 
human NAT1 also was measured with an endogenous folate compound 
dihydrofolate. The rat Nat2 gene is a functional ortholog for the human NAT1 
because it has similar sequence and substrate specificity to human NAT1. Rapid 
acetylator NAT2 congenic rats developed more mammary tumors than the slow 
acetylator NAT2 congenic rats following administration of the mammary 
vi	
carcinogens methylnitrosourea and 7,12-dimethylbenzanthracene, neither of 
which is metabolized by rat NAT2. Investigations of partial NAT1 knockdown and 
complete NAT1 knockout were completed in MDA-MB-231 and MCF7 human 
breast cancer cell lines. Both partial and complete NAT1 knockout reduced ability 
for colony formation in soft agar compared to parental cell lines. Endogenous 
AcCoA levels in congenic rat embryonic fibroblasts and in human breast cancer 
cell lines with partial and complete NAT1 knockout showed increased AcCoA 
when the level of NAT1 was reduced within the cells. In summary, the findings 
compliment but do not fully replicate previous reports regarding the effect of 
reducing NAT1 activity on cancer cell properties. In our studies, partial 
knockdown or complete removal of NAT1-catalyzed N-acetylation in the MDA-
MB-231 and MCF7 breast cancer cell line by CRISPR/Cas9 resulted in a 
significant decrease in anchorage-independent colony formation without affecting 
overall cell growth and relative invasion ability. NAT1 knockout cell lines had 
increased endogenous AcCoA levels, about 45%, compared to the parental cell 
line. The results warrant further studies to determine mechanisms to understand 
how reduced NAT1 activity is related to reduced formation of anchorage-
independent colonies. Use of this model system further suggests that human 
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The human genome codes for two functional arylamine N-
acetyltransferases (NATs), NAT1 and NAT2, that are located on the short arm of 
chromosome 8 [1]. Human NAT1 is expressed in nearly all human tissues [2, 3]. 
Human NAT2 is expressed primarily in the liver and gut [4]. The two NATs differ 
from each other in substrate specificity, structural stability, and tissue specific 
expression [5]. There is also an inactive NAT pseudogene known as NATP [6].  
The NAT1 protein is a phase II cytosolic isoenzyme responsible for the 
metabolism of arylamine xenobiotics, including such environmental and 
occupational carcinogens like 4-aminobiphenyl (ABP)[7]. NAT1 catalyzes both N-
acetylation and O-acetylation. The N-acetylation of aromatic and heterocyclic 
amine xenobiotics results in the inactivation of compounds, and the inactivated 
compound is removed by urinary excretion. After N-hydroxylation of aromatic and 
heterocyclic amine xenobiotics by a cytochrome P450, O-acetylation catalyzed 
by NAT1 produces an unstable highly reactive nitrenium ion. This nitrenium ion is 
able to react with DNA forming DNA adducts, which if left unrepaired generate 
mutations leading to cancer initiation. NAT1 is related to several cancer types by 
its ability to biotransform arylamine procarcinogens to active carcinogen forms. 
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However recent findings suggest that human NAT1 activity is involved in cancer 
by a still unknown mechanism independent of procarcinogen metabolism. 
Research in cancer biology has provided insights into the connections of 
NAT1 and cancer cell proliferation and invasiveness. Overexpressing human 
NAT1 in non-transformed breast epithelial cells, HB4a, resulted in increased 
growth and survival. These modified cells also showed a resistance to etoposide 
treatment [8]. Calu3 cells, a colon carcinoma cell line, that are resistant to 
gemcitabine have higher expression of NAT1 [9]. In a majority of human 
immortalized cells assayed there has been endogenous NAT1 expression/activity 
observed [10]. The use of a lentiviral shRNA expression system for human NAT1 
knockdown in a human breast cancer cell line, MDA-MB-231, caused a decrease 
in cell proliferation and invasiveness [11, 12]. Similarly, NAT1 knockdown in a 
human colon cancer cell line, HT-29 showed increased cell-cell contact inhibition 
[13]. Up-regulation of E-cadherin was associated with knockdown of human 
NAT1, but there was no change in the transcription factors Snail, Twist, or Slug 
[13, 14]. Use of a small molecule inhibitor, Rhod-o-hp, specific for human NAT1 
showed that inhibition in MDA-MB-231 cells stops cell proliferation, inhibited 
anchorage-independent growth, and reduced the invasiveness of the cell [11]. All 
the cell culture experiments indicate that human NAT1 plays some role in cancer 
cell proliferation and survival. 
Microarray data on many different types of breast cancer showed NAT1 
expression was clustered with estrogen receptor expression [15, 16]. This 
correlation between positive estrogen receptor (ER) status and human NAT1 was 
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confirmed by additional microarray studies [17-20]. Immunohistochemistry 
showed higher human NAT1 levels in ER+ breast cancer samples when 
compared to ER- breast cancer [8]. Expression also is affected by the deletion of 
NAT1’s chromosome region in some cancers. The deletion may explain why 
some cancer subtypes have low expression of NAT1 [21]. Tumors, characterized 
based on which breast tissue the tumor arose from, showed luminal breast 
cancers with higher NAT1 expression than basal breast cancer [16, 22, 23]. A 
significant correlation has been observed between breast carcinomas expressing 
the highest levels of NAT1 and those that metastasized to the bone [24]. Also, 
elevated human NAT1 mRNA level has been shown to be associated with more 
invasive breast cancers [25]. All this evidence for the relationship of NAT1 with 
some subtypes of breast cancer has led some to state a possible role of NAT1 in 
classifying cancer molecular subtypes.  
Human populations exhibit different NAT1 variant haplotypes. The 
reference haplotype is termed NAT1*4. NAT1*10 is known as one of the most 
common variant haplotypes. NAT1*10 is presently defined by two SNPs 
1088T>A (rs1057126) and 1095C>A (rs15561) in the 3’ UTR 
(http://nat.mbg.duth.gr). NAT1*10 is associated with increased NAT1 activity in 
human bladder [26], colon [27], and liver [28]. NAT1*10 also is associated with 
higher cancer risk in some types of cancer. NAT1*10 has been associated with 
higher risk of developing cancer in the breast [29], colon/rectum [30, 31], lung 
[32], pancreas [33], and urinary bladder [34]. However, other studies have 
reported no association between NAT1*10 and cancer risk [35, 36]. 
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NAT1*14B is the most common variant allele that is associated with a 
reduced acetylator activity. Allelic frequencies in American, German, French, and 
Canadian populations are less than 5% [7]. However the allelic frequency of 
NAT1*14B in the Lebanese population is about 24% [37]. NAT1*14B is defined 
presently by a SNP of nucleotide G560A (rs4986782), which is located in the 
open reading frame (ORF) (http://nat.mbg.duth.gr). G560A results in an amino 
acid substitution R187Q. The arginine for glutamine substitution is thought to 
destabilize the NAT1 structure. The use of homology modeling predicts that the 
substitution affects NAT1 binding of acetyl-coenzyme A, active site acetylation, 
catalytic activity, and substrate specificity [38]. NAT1*14B is associated with 
smoking-induced cancer [39]. 4-Aminobiphenyl (ABP) DNA adducts are elevated 
in cells that have been stably transfected with NAT1*14B compared with cells 
transfected with NAT1*4 (considered the wildtype allele) [40].  
In summary human NAT1 is involved in cancer cell proliferation and 
survival. Human NAT1 has been found to correlate with aggressive forms of 
cancer and estrogen receptor positive breast cancer. Human NAT1 haplotypes 
that have the highest activity stand at a higher risk for certain types of cancer. 
This evidence shows that NAT1 has a role in cancer, but the exact mechanism of 




FOLATE-DEPENDENT HYDROLYSIS OF ACETYL-COENZYME A BY 




Arylamine N-acetyltransferases (NATs) are phase II cytosolic isoenzymes 
responsible for the metabolism of arylamine and N-hydroxylarylamine drugs and 
xenobiotics [41]. The isoenzymes catalyze the transfer of the acetyl group from 
acetyl-coenzyme A (AcCoA) to the exocyclic amine of an arylamine (N-
acetylation) or the hydroxylated amine of an N-hydroxylated arylamine (O-
acetylation) [42-44]. NATs are able to bioactivate procarcinogens like 4-
aminobiphenyl (ABP), a component of cigarette smoke [41]. Also, NATs 
metabolize various pharmaceuticals, such as the antibacterial (sulfonamides), 
antitubercular (isoniazid), and antiarrhythmic (procainamide) drugs [45-47]. 
Understanding N-acetyltransferase function, expression, and regulation aids in 
predicting individual drug toxicities or individual tissue-specific cancer 





Amino acid residues at positions 125, 127, and 129 determine substrate 
specificity of the 290 amino acid NAT1 protein [48]. Comparison of the amino 
acids at the three mentioned positions in rat Nat2 and mouse Nat2 with human 
NAT1, shows they share all three amino acids (Phe125, Arg127, and Tyr129). 
However hamster Nat2 shares only two out of three amino acids (Phe125 and 
Arg127) with human NAT1. This shared amino acid similarity suggests that these 
NATs will have similar substrate specificity. The C-terminus undecapeptide tail of 
the NATs controls the hydrolysis of AcCoA [49]. The C-terminus undecapeptide 
tail of rat, mouse, and hamster Nat2 and human NAT1 share 100% identical 
amino acids suggesting they are orthologs. Conversely rodent Nat1 and human 
NAT2 do not align as well as rodent Nat2 and human NAT1. Only rat Nat1 
(Tyr125, Ser127, and Tyr129) shares a single similar amino acid for the active 
site in human NAT2 (Ser125, Ser127, Ser129). The mouse and hamster Nat1 
(Tyr125, Gly127, Tyr129) share the same active site amino acids with each 
other, but do not share any similarity to human NAT2. The C-terminus 
undecapeptide tails for rodent Nat1 and human NAT2 also do not have much in 
common. Rodents have an active Nat3 enzyme, unlike humans [1, 50]. 
 
N-acetyltransferases have been shown to play a role in development [51]. 
It has been proposed that human NAT1 influences folate homeostasis and thus, 
affects neural tube development [52]. Human NAT1 acetylates the folate 
catabolite, para-aminobenzoyl-1-glutamate [53]. Recent studies report that 
human NAT1 and mouse Nat2 hydrolyze AcCoA into acetate and coenzyme A in 
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a folate-dependent fashion [54], a previously unknown function (figure 2.1). In 
this chapter, our goal was to confirm these findings and determine the apparent 
Michaelis-Menten kinetic constants (Vmax and Km) of the folate-dependent 
AcCoA hydrolysis for human NAT1/NAT2 and the rodent analogs rat Nat1/Nat2, 
mouse Nat1/Nat2, and hamster Nat1/Nat2. We also compared apparent Vmax 
values for AcCoA hydrolysis to N-acetylation of the substrate para-aminobenzoic 








Figure 2.1. NAT1 enzymatic reactions are AcCoA-dependent N-acetylation of 
arylamine substrate (A) and folate-dependent hydrolysis of AcCoA in absence of 







Arylamine N-acetyltransferases Recombinant Expression 
Methods for the cloning and expression of the recombinant human and 
rodent arylamine N-acetyltransferases have been reported in previous 
publications from our laboratory for human [55], rat [56], mouse [57], and 
hamster [58, 59]. In brief, JM105 Escherichia coli strain was transformed with 
NAT containing pkk223-3 plasmid. The transformed JM105 E. coli was picked as 
a single colony and cultured overnight in 50 ml LB media containing ampicillin 
(100 µg/ml) at 37 °C. The following day, 4 ml of the overnight culture was added 
to 200 ml fresh sterile LB media containing ampicillin (100 µg/ml) and grown until 
the optical density (OD600nm) reached 0.4-0.6. Expression of N-acetyltransferases 
was induced by addition of isopropyl β-D-thiogalactopyranoside (final 
concentration 1 mM) for 3 h. Cells were harvested by centrifugation at 5000 x g 
for 10 min at 4 °C and the cell pellet was suspended in 10 ml of ice-cold 20 mM 
sodium phosphate pH 7.4, 1 mM dithiothreitol, 1 mM EDTA, 0.2% triton-x-100, 
100 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, and 1 µg/ml aprotinin. 
The solution was sonicated on ice 6 times for 30 sec. The lysate was centrifuged 







PABA N-acetylation Assays 
PABA N-acetylation assays were done as previously described [60]. 
Briefly, recombinant lysate was added to a mixture of PABA (Sigma Aldrich) and 
AcCoA (Amersham Biosciences), whose final concentrations in the reaction were 
150 µM and 400 µM, respectively. The mixture was incubated at 37 °C for 10 
min, after which the reaction was quenched with 1/10 volume of 1 M acetic acid. 
Precipitated proteins were removed by centrifugation. Supernatants were 
injected on a C18 column and reaction substrates and products separated and 
quantitated using Beckman System Gold high performance liquid 
chromatography (HPLC). 
 
AcCoA Hydrolysis Assays 
Recombinant lysates were added to folate (Sigma-Aldrich) and AcCoA. 
Initial reactions were carried out at 37 °C with fixed concentrations of folate (500 
µM) and AcCoA (400 µM) to determine appropriate enzyme lysate dilutions for 
subsequent reactions. Next, reactions were performed to determine Michalis-
Menton constants for AcCoA. Reactions were done at 500 µM folate and varying 
AcCoA concentrations from 0 µM to 400 µM. The third set of reactions was done 
with AcCoA fixed at 400 µM for mouse and hamster and 200 µM for human and 
rat with folate concentrations varied between 0 and 400 µM. Control reactions 
were done with the same enzyme and AcCoA concentration but no folate. The 
amounts of CoA produced in the minus folate reactions were subtracted from 
reactions containing folate to determine folate-dependent hydrolysis.  
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Recombinant human NAT1 lysates were used to compare the ability of 
AcCoA hydrolysis dependent on folate analogs methotrexate (MTX) (Sigma 
Aldrich) and dihydrofolate (DHF) (Sigma Aldrich). Reactions were carried out at 
37 °C with fixed concentrations of folate/MTX/DHF (300 µM) and AcCoA (500 
µM) for 10 mins. Control reactions were done with the same enzyme and AcCoA 
concentration but no folate analogs. The amounts of CoA produced in the minus 
folate reactions were subtracted from reactions containing folate to determine 
folate-dependent hydrolysis. 
 
The reaction mixtures were incubated at 37 °C for 10 min, after which the 
reaction was quenched by adding 1/10 volume of perchloric acid (15% w/v). The 
precipitated protein was removed by centrifugation and the supernatant was 
injected onto a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µM pore 
size). Reactants and products were separated and quantitated by HPLC. 
Separation of CoA, acetyl CoA, and folate was achieved using a linear gradient 
of 100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium 
phosphate pH 4.0: 100% methanol over 20 min and was quantitated by 
absorbance at 260 nm. The limit of detection for CoA was 0.05 nmoles/min/mg of 
protein. 
 
Inhibition of PABA N-acetylation Activity with Folate Analogs 
Recombinant human NAT1 lysates were added to a mixture of AcCoA 
(400 µM), with varying folate/MTX (0, 100, 200, 300, 400, 500 µM), and varying 
	
	 12	
PABA (0, 50, 100, 200, and 400 µM). The mixtures were incubated at 37 °C for 
10 min, after which the reaction was quenched with 1/10 volume of 1 M acetic 
acid. Precipitated proteins were removed by centrifugation. Supernatants were 
injected on a C18 column and reaction substrates and products separated and 
quantitated using Beckman System Gold high performance liquid 
chromatography (HPLC) as described above. 
 
Statistics 
 All the data are shown as mean ± SEM from three separate 
determinations. The Michaelis-Menten constants (Km and Vmax) were 
determined by nonlinear regression of the Michaelis-Menten equation (GraphPad 




Michaelis-Menton Saturation Curves for AcCoA Hydrolysis 
AcCoA hydrolysis with (figure 2.2, solid line) or without (figure 2.2, dash 
line) the addition of folate (both in the absence of any arylamine NAT1 substrate) 
was determined for recombinant human NAT1 and rodent Nat2. Some hydrolysis 
of AcCoA to form CoA was observed in the absence of folate (figure 2.2). Since 
this folate-independent hydrolysis of AcCoA to form CoA was also observed in 
bacterial lysates from recombinantly expressed vector controls, this folate-
independent hydrolysis of AcCoA was subtracted from folate-dependent AcCoA 
hydrolysis rates in the subsequent measurements described below.  
 
AcCoA Hydrolysis and N-acetylation Activities of Recombinant 
Human NAT1 and NAT2 
For human NAT1 the apparent Vmax and Km values determined for 
AcCoA in the AcCoA hydrolysis reaction were 111 ± 13 nmoles/min/mg protein 
and 54.3 ± 20.5 µM, respectively (figure 2.3A, solid line). For human NAT1 the 
apparent Vmax and Km values determined for folate in the AcCoA hydrolysis 
reaction were 200 ± 18 nmoles/min/mg protein and 85.2 ± 21.5 µM, respectively 
(figure 2.3A, dash line). Initial rate constant for PABA N-acetylation activity for 
recombinant human NAT1 was 20300 ± 1720 nmoles/min/mg protein. Human 
NAT2 AcCoA hydrolysis activity was below the level of detection (0.05 







Figure 2.2. Michaelis-Menton saturation curves for AcCoA hydrolysis with 
(circles with solid line) or without (squares with dashed line) 500 µM folate (with 
no arylamine substrate present). Hydrolysis activity was catalyzed by human 
NAT1 (A) and rodent Nat2s (B-D). Data points represent results from three 





AcCoA Hydrolysis and N-acetylation Activities of Recombinant Rat 
Nat1 and Nat2 
For rat Nat2 the apparent Vmax and Km values determined for AcCoA in 
the AcCoA hydrolysis reaction were 13.5 ± 2.6 nmoles/min/mg protein and 126 ± 
60 µM, respectively (figure 2.3B, solid line). For rat Nat2 the apparent Vmax and 
Km values determined for folate in the AcCoA hydrolysis reaction were 7.61 ± 
0.78 nmoles/min/mg protein and 29.5 ± 14.0 µM, respectively (figure 2.3B, dash 
line). Initial rate constant for PABA N-acetylation activity for recombinant rat Nat2 
was 3030 ± 274 nmoles/min/mg protein. Rat Nat1 AcCoA hydrolysis activity was 
below the level of detection (0.05 nmoles/min/mg of protein). 
 
AcCoA Hydrolysis and N-acetylation Activities of Recombinant 
Mouse Nat1 and Nat2 
For mouse Nat2 the apparent Vmax and Km values determined for AcCoA 
in the AcCoA hydrolysis reaction were 130 ± 9 nmoles/min/mg protein and 88.3 ± 
18.3 µM, respectively (figure 2.3C, solid line). For mouse Nat2 the apparent 
Vmax and Km values determined for folate in the AcCoA hydrolysis reaction 
were 120 ± 14 nmoles/min/mg protein and 77.1 ± 27.9 µM, respectively (figure 
2.3C, dash line). Initial rate constant for PABA N-acetylation activity for 
recombinant mouse Nat2 was 32600± 1170 nmoles/min/mg protein. Mouse Nat1 





AcCoA Hydrolysis and N-acetylation Activities of Recombinant 
Hamster Nat1 and Nat2 
For hamster Nat2 the apparent Vmax and Km values determined for 
AcCoA in the AcCoA hydrolysis reaction were 200 ± 13 nmoles/min/mg protein 
and 164 ± 24 µM, respectively (figure 2.3D, solid line). For hamster Nat2 the 
apparent Vmax and Km values determined for folate in the AcCoA hydrolysis 
reaction were 186 ± 5 nmoles/min/mg protein and 94.0 ± 6.5 µM, respectively 
(figure 2.3D, dash line). Initial rate constants for PABA N-acetylation activity for 
recombinant hamster Nat2 was 20700 ± 1350 nmoles/min/mg protein. Hamster 
Nat1 AcCoA hydrolysis activity was below the level of detection (0.05 
nmoles/min/mg of protein). 
 
Comparison of AcCoA Hydrolysis to PABA N-acetylation 
Human NAT1 and rodent Nat2 lysates were able to N-acetylate PABA. 
The percentages of the AcCoA hydrolytic activity (Vmax) for human NAT1 and 
rodent Nat2 lysates were 0.25 to 1% relative to the initial rate constant for PABA 








Figure 2.3. Michaelis-Menton saturation curves with various concentrations of 
AcCoA (solid line) and folate (dashed line) for human NAT1 (A), rat Nat2 (B) 
mouse Nat2 (C) and hamster Nat2 (D). Hydrolysis activity in nmol/min/mg protein 
is plotted on the ordinate versus substrate concentration on the abscissae. Folate 
concentration was fixed at 500 µM for AcCoA Vmax and Km determinations. 
AcCoA concentration was fixed at 200 µM for human NAT1 and rat Nat2 and 400 
µM for mouse Nat2 and hamster Nat2 folate Vmax and Km determinations. Data 






Table 2.1 - Comparisons of PABA N-acetylation and AcCoA hydrolysis by recombinant human NAT1 and rodent Nat2 
enzymes. 
  AcCoA Hydrolysis     Apparent hydrolytic 
  Apparent Vmax (nmol/min/mg)  PABA N-acetylation  Vmax/PABA acetylation 
  AcCoA  Folate  (nmol/min/mg)  AcCoA (%)  Folate (%) 
Human NAT1 111 ± 13  200 ± 18  20300 ± 1720  0.547%  0.985% 
Rat Nat2 13.5 ± 2.6  7.61 ± 0.78  3030 ± 274  0.446%  0.251% 
Mouse Nat2 130 ± 9  120 ± 14  32600 ± 1170  0.399%  0.368% 
Hamster Nat2 200 ± 13  186 ± 5  20700 ± 1350  0.966%  0.899% 




Recombinant Human NAT1 AcCoA Hydrolysis Activity with Folate, 
MTX, and DHF 
Human NAT1 hydrolyzed AcCoA in the presence of folate with a rate of 
104 ± 10.2 nmoles/min/mg protein (figure 2.4B). Human NAT1 hydrolyzed 
AcCoA in the presence of DHF at a rate of 85.6 ± 9.13 nmoles/min/mg protein 
(figure 2.4B). Human NAT1 hydrolyzed AcCoA in the presence of the folate 
analog MTX at a very low rate of 2.50 ± 0.920 nmoles/min/mg protein (figure 
2.4B). Folate-and DHF-dependent hydrolysis rates did not differ significantly 
(p>0.05) from each other but both were significantly (p<0.001) elevated 
compared to the level of MTX-dependent hydrolysis (figure 2.4B). 
 
Inhibition of N-acetylation of PABA by Recombinant NAT1 with 
Folate and MTX 
Increasing the folate concentrations served to inhibit human NAT1 PABA 
acetylation activity in a dose-dependent manner (figure 2.5A). Additionally the 
increasing MTX concentrations served to inhibit the amount of acetylated PABA 
produced by human NAT1 (figure 2.5B). The IC50’s for folate and MTX were 








Figure 2.4. The chemical structures (A) depicting folate, DHF, and MTX. Level of 
AcCoA hydrolysis catalyzed by NAT1 with the addition of folate, MTX, and DHF 
(B). MTX had significantly lower level of activity than folate or DHF. Data points 
represent mean ± SEM from three separate determinations. The number of 












































Figure 2.5. Michaelis-Menton curves showing inhibition by folate (A) or MTX (B) 
on NAT1 PABA acetylation activity with increasing PABA concentration. The 
concentrations of folate and MTX are 0, 100, 200, 300, 400, and 500 µM.  
Folate (C) and MTX (D) inhibit PABA acetylation activity, when PABA is held 





























































































LogIC50 = 1.886 ± 0.01970 µM


































LogIC50 = 2.103 ± 0.02593 µM
































Folate is a water soluble B vitamin found in various foods (leafy green 
vegetables, organ meat, etc.), and is commonly used to fortify foods. Commercial 
fortification was mandated to prevent developmental defects in early fetal 
development. However, of growing interest and experimentation is whether folate 
levels in the body and folic acid supplementation affects tumor induction and 
progression [61].  
	
Our study has confirmed that human NAT1 and the rodent ortholog mouse 
Nat2 are capable of AcCoA hydrolysis in the presence of folate but absence of 
xenobiotic substrate (e.g. PABA) as shown by Laurieri et al. [54]. This study also 
confirmed that folate is not consumed in the hydrolysis reaction and that human 
NAT2 and mouse Nat1 do not perform this reaction to any significant degree. In 
addition, we have shown that hamster and rat Nat2 enzymes also catalyze this 
AcCoA hydrolysis, while the hamster and rat Nat1 has no detectable AcCoA 
hydrolysis activity. A new methodology was developed in the study to measure 
the level of CoA and AcCoA by HPLC. We determined the Michaelis-Menton 
kinetic constants (Vmax and Km) for both AcCoA and folate using human NAT1 
as well as three rodent Nat2 enzymes.  
 
Human NAT1 had Vmax and Km values similar to hamster and mouse 
Nat2 but different from rat Nat2 for both varying AcCoA and folate 
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concentrations. Also, when comparing Vmax and Km values for folate and 
AcCoA among the individual human and rodent enzymes they also appeared to 
be surprisingly similar. The Vmax for AcCoA hydrolytic activity was less than 1% 
of the PABA N-acetylation activity for the same enzyme. The total body content 
of folate is estimated to be 10 to 30 mg; about half of this amount is stored in the 
liver and the remainder is in blood and body tissues [62]. Erythrocyte folate 
concentrations in the USA and Canada recently were reported from 0.5 to 2.5 
nmol/L but varied with assay method, diet and supplementation. Modest 
correlations recently were reported between plasma and breast folate 
concentrations suggesting that plasma levels may not predict concentrations of 
folate in various tissues [63]. Future studies with NAT2 knock out mice [52] or 
congenic Nat2 rapid and slow acetylator rats [64] may help to determine whether 
changes in level of human NAT1 (rodent Nat2) expression could affect AcCoA 
levels in vivo and thus possibly affect cellular metabolism. The next chapter 
describes congenic rat embryonic fibroblasts (REFs) used to compare 
endogenous AcCoA levels. Slow acetylator congenic REFs showed higher 
endogenous AcCoA levels than the rapid acetylator congenic REFs [65]. 
 
Folate is commonly considered to have a low abundance within the 
mammalian cell, being reduced to dihydrofolate (DHF) upon entering the cell. 
DHF is then reduced further resulting in other folate derivatives. Derivatives past 
DHF are considered unstable and are not readily, commercially available with a 
high level of purity. The instability of endogenous folate compounds makes the 
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measurement of AcCoA hydrolysis dependent on endogenous folate compounds 
complex. Fortunately, DHF is commercially available at 90% or more purity and 
moderately stable. Human NAT1 is able to hydrolyze AcCoA in the presence of 
DHF similar to folate, but not with an analog for folate and DHF, MTX. 
Structurally DHF has one additional hydrogen compared to folate. Folate and 
DHF compared to MTX differ mainly by the addition of one methyl group and an 
amine group. MTX being unable to significantly stimulate AcCoA hydrolysis, 
raises the questions of whether MTX is able to interact with the active site of 
NAT1 and how similar endogenous folate derivatives stimulate AcCoA hydrolytic 
activity by NAT1. 
 
While MTX is almost unable to support the hydrolysis of AcCoA by NAT1, 
it is able to inhibit the N-acetylation of PABA like folate (figure 2.5B). The similar 
inhibition abilities of folate and MTX suggest that both folate and MTX are able to 
interact with the active site. This interaction blocks substrates from entering the 
deep pocket of the NAT1 enzymatic active site. The shared interaction with the 
active site leaves the question, what chemical structural elements in folate allow 
for the release the acetyl group from the acetylated cysteine since MTX is unable 
to perform a similar function.  
 
In summary, our results are consistent with the possibility that human 
NAT1 and its rodent Nat2 orthologs regulate endogenous AcCoA levels in a 
folate-dependent reaction. The results suggest associations of human NAT1 
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activity with disease or tumor progression may be related to regulation of AcCoA. 
The regulation of AcCoA levels will be analyzed in the following chapters. Further 
studies are needed to explore how some folate compounds support the 




CONGENIC RATS WITH HIGHER ARYLAMINE N-ACETYLTRANSFERASE 2 
ACTIVITY EXHIBIT GREATER CARCINOGEN-INDUCED MAMMARY TUMOR 
SUSCEPTIBILITY INDEPENDENT OF CARCINOGEN METABOLISM 
INTRODUCTION 
Human arylamine N-acetyltransferase 1 (NAT1) is a cytosolic isoenzyme 
responsible for the N-acetylation of arylamine xenobiotics, including 
environmental and occupational carcinogens such as 4-aminobiphenyl 
(ABP)[41]. NAT1 is located on the short arm of chromosome 8 (8p22) and is 
expressed in nearly all human tissues [2, 3]. NAT1 catalyzes both O-acetylation 
and N-acetylation. One role for NAT1 in carcinogenesis is its ability to 
biotransform arylamine procarcinogens to active carcinogens [66]. Recent 
findings in vitro suggest that NAT1 activity level also may influence cancer cell 
proliferation and survival [8, 10, 11, 13]. 
 
NAT1 activity is modified by genetic polymorphism, but also can be 
regulated by microRNA, epigenetic, and/or translational and post-translational 
control features [67-70]. NAT1 transcript levels are regulated by extracellular 
stimuli acting on glucocorticoid receptor or androgen receptor [71, 72]. Exposure 
to NAT1 substrates can increase NAT1 degradation [69, 70]. Some 
polymorphisms in humans destabilize the enzyme, leading to greater 
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polyubiquitin-dependent degradation [69]. NAT1*10, the most common 
haplotype, is associated with increased NAT1 activity in human bladder [26], 
colon [27], and liver [28]. NAT1*10 has been associated with higher risk of 
developing cancers of the breast [29], colon/rectum [30, 31], lung [32], pancreas 
[33], and urinary bladder [34]. However, other studies have reported no 
association between NAT1*10 and cancer risk [35, 36].  
 
Rat arylamine N-acetyltransferases are similar in sequence and function 
to human N-acetyltransferases [48, 50, 73]. Rat models have been used for the 
study of arylamine N-acetyltransferases [73-75]. Rat NAT2 and human NAT1 
active sites both contain Phe125, Arg127, and Tyr129, consistent with their 
similar arylamine substrate selectivity [48]. The C-terminal undecapeptide, which 
is involved in controlling acetyl-coenzyme A (AcCoA) hydrolysis [49], is 100% 
identical when comparing rat NAT2 and human NAT1. Rat Nat2 and human 
NAT1 are orthologs as shown by their amino acid sequence similarity (figure 
3.1). 
 
Rats, like humans, have different NAT2 haplotypes. Homozygous rapid 
(F344) and slow (WKY) acetylator inbred rats have been characterized as rapid 
and slow NAT2 acetylators, respectively [75, 76]. Slow acetylator WKY inbred 
rats are homozygous for a rat Nat2 allele with four single nucleotide 
polymorphisms (SNPs): G361A (Val121→ Ile), G399A (synonymous), G522A 
(synonymous), and G796A (Val266→ Ile), as compared to the Nat2 allele in the 
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F344 strain rapid-acetylator Nat2 allele [56] (figure 3.1). These two inbred rat 
stains were used in the development of congenic F344.WKY rats with either high 







 N-TERMINUS END    
HUMAN NAT1-1	 MDIEAYLERI	 GYKKSRNKLD	 LETLTDILQH	 QIRAVPFENL	 NIHCGDAMDL	
RAT	NAT2-1	 MDIEAYFERI	 GYQSSRNKLD	 LEELTEILQH	 QIRAIPFENL	 NIHCGESMEL	
HUMAN NAT1-51	 GLEAIFDQVV	 RRNRGGWCLQ	 VNHLLYWALT	 TIGFETTMLG	 GYVYSTPAKK	
RAT	NAT2-51	 NLEVIFDQVV	 RKKRGGWCLQ	 VNHLLYWALT	 KMGFEATMLG	 GYVFNTPANK	
HUMAN NAT1-101	 YSTGMIHLLL	 QVTIDGRNYI	 VDAGFGRSYQ	 MWQPLELISG	 KDQPQVPCVF	
RAT	NAT2-101	 YSSGMIHLLV	 QVTLSGKDYI	 VDAGFGRSYQ	 MWEPLELTSG	 KDQPQVPAIF	
HUMAN NAT1-151	 RLTEENGFWY	 LDQIRREQYI	 PNEEFLHSDL	 LEDSKYRKIY	 SFTLKPRTIE	
RAT	NAT2-151	 RLTEENGTWY	 LDQIRREQYV	 PNQEFVNSDL	 LEKNKYRKIY	 SFTLEPRTIE	
HUMAN NAT1-201	 DFESMNTYLQ	 TSPSSVFTSK	 SFCSLQTPDG	 VHCLVGFTLT	 HRRFNYKDNT	
RAT	NAT2-201	 DFESINTYLQ	 TSPASLFTSK	 SFCSLQTLEG	 VHCLVGSTLT	 YRRFSYKDNI	
HUMAN NAT1-251	 DLIEFKTLSE	 EEIEKVLKNI	 FNISLQRKLV	 PKHGDRFFTI	 290	AA	
RAT	NAT2-251	 DLVEFKSLTE	 EEIEDVLKTI	 FGVSLERKLV	 PKHGDRFFTI	 290	AA	
	   C-TERMINUS END ~83%	
 
 
Figure 3.1. Amino acid sequence comparison between human NAT1 and rat 
Nat2. The gray highlighting indicates areas were the amino acids differ between 
the two enzymes. The two enzymes are 83 % identical to each other. The yellow 
highlighted regions indicate the areas of importance to the enzymes, the c-
terminus tail and the three critical amino acids in the active site. The two 
enzymes share 100% identity in the active site and c-terminus tail. In the rat 
amino acid sequence there are two underlined amino acids, Val121 and Val266. 
Both valines are isoleucines in the slow phenotypic rats, whereas they are 




Breast tumors have been induced for several decades with the 
administration of methylnitrosourea (MNU). MNU is a simple alkylating agent, 
which places a methyl group on oxygen and nitrogen of macromolecules, like 
DNA. It has been shown previously that sexually immature F344 rats (at 3 weeks 
of age) are more susceptible to mammary carcinogenic effects from MNU than 
mature rats (8 weeks of age) [77].  
 
The mechanism for how MNU causes cancer is by DNA damage resulting 
from the alkylation of nitrogen and oxygen in DNA leading to mutations. N7-
alkylguanine, N3-alkyladenine, and O6-alkylguanine account for 68%, 8%, and 
7.5% of total methylation after MNU treatment, respectively [78]. The N7 atom of 
guanine is the most vulnerable site for attack by alkylating agents; however N7-
alkylguanine alone has no pronounced mutagenic and cytotoxic effect [79]. 
Alkylation of the N7 atom does cause chemical instability at the N-glycosidic 
bond, causing spontaneous abasic/apurinic sites to form. Abasic sites also form 
in the repair of N7-alkylguanine by N-alkylpurine DNA-glycosylases, enzymes in 
the BER pathway. The mutagenic and toxic effects of abasic sites have been well 
described previously [80]. N3-alkyladenine is not particularly mutagenic, but it is a 
cytotoxic DNA lesion because it is able to block replication and able to generate 
abasic sites [79]. N3-alkyladenine has been shown to cause sister chromatid 
exchange, chromosome gaps and breaks, S phase arrest, accumulation of p53, 
and apoptosis in mammalian cells [81]. O6-alkylguanine is the primary mutagenic 
lesion under most conditions of alkylation damage to the genome causing G →A 
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transitions after two replications [79, 82] (figure 3.2). In addition to the point 
mutations following DNA replication, O6-alkylguanine can also result in mismatch 
repair-mediated DNA recombination and cell death [83]. Repair by mismatch 
repair system at O6-alkylG:T can form the “futile cycle”. The “futile cycle” occurs 
when repair enzymes recognize mismatch of G:T and remove the newly 
incorporated thymidine opposite of O6-alkylguanine. Then, the sequence is 
replicated again and the O6-alkylguanine preferentially pairs with thymine, once 
more, thus reinitiating the repair and replication cycle [79, 82, 84, 85]. This 
persistent cycling of mismatch repair can generate a stabilized nick or gap in one 
strand of DNA, which may activate damage signaling pathways and DNA 
recombination [84]. Even with this futile cycling, it has been found that O6-
alkylguanine lesions went from being 10% mutagenic in cells with repair 
capability to nearly 100% mutagenic in cells without DNA repair abilities [86]. In 
total the resulting alkylation of nitrogen and oxygen in DNA by a simple direct 
acting carcinogen, MNU, shows how cancer can result without rat NAT2 playing 






Figure 3.2. Mechanistic diagram for how MNU damages DNA. MNU alkylates 
guanine, which can be repaired immediately by O6-alkylguanine-DNA 
alkyltransferase (MGMT), also known as O6-alkylguanine-DNA alkyltransferase 
(AGT). However if not repaired before replication, translesion DNA synthesis 
(TLS) will be done. TLS mismatches the nucleotide causing three possible 
pathways. The one on the left is that another TLS occurs resulting in a 
permanent mutation that can allow the cell to survive. The second possibility is 
on the right and is a direct signaling pathway that tells the cell to undergo 
apoptosis. The middle one is where the mismatch repair pathway tries to correct 
the mismatch of G:T and removes the newly incorporated thymidine opposite of 
O6-alkylguanine. Then, the sequence is replicated again and the O6-alkylguanine 
preferentially pairs with thymine, once more, thus reinitiating the repair and 
replication cycle. This reoccurring cycling is termed the “futile cycle” Futile cycle 
can generate a stabilized nick or gap in one strand of DNA, which can cause 
replication fork collapse and a double strand DNA break (DSB). The DSB can be 
repaired by non-homologous end-joining (NHEJ) pathways, which can lead to 
cell survival but with mutations, sister chromatid exchange (SCE), or 
chromosomal aberrations. If the DSB is not repaired, cellular programing will be 
triggered to lead the cell into apoptosis. This figure has been modified from one 




7,12-dimethylbenzanthracene (DMBA) is a polycyclic aromatic 
hydrocarbon compound that is known for its carcinogenic properties. DMBA is 
extensively used in rodent models for breast, skin, and other cancers [88]. 
DMBA, similar to other polycyclic aromatic hydrocarbon compounds, requires 
bioactivation to an active carcinogen. DMBA is initially metabolized by 
cytochrome P450 to DMBA-3,4-oxide, then to DMBA-3,4-diol by epoxide 
hydrolase, and finally metabolized again by cytochrome P450 to DMBA-3,4-diol-
1,2-epoxide [89, 90]. The enzymes responsible for this bioactivation of DMBA are 
cytochrome P4501B1 (CYP1B1) and microsomal epoxide hydrolase (EPHX1) 
[91]. CYP1B1 is thought of as the main enzyme in DMBA metabolism for humans 
and rodents [92]. DMBA-3,4-diol-1,2-epoxide is the active metabolite of DMBA 
that results in DNA adduct formation. The resulting DNA adducts are associated 
with DNA mutations and malignant transformation [93, 94]. As with MNU, DMBA 
has an established mechanism for cancer development without rat NAT2 playing 
a direct metabolizing role.  
 
In this chapter, rapid (F344.WKY-Nat2rapid) and slow (F344.WKY-Nat2slow) 
acetylator rat strains were utilized to investigate mammary cancer risk following 
the administration of methylnitrosourea (MNU) or 7,12-dimethylbenzanthracene 
(DMBA), neither of which is biotransformed by rat NAT2 [89, 95-97]. The two 
carcinogens are extensively researched and characterized. MNU is known to be 
a direct acting carcinogen, which will eliminate any differences caused by 
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metabolism of a pro-carcinogen. DMBA is a well characterized pro-carcinogen 





MATERIALS AND METHODS 
Rapid and Slow Acetylator Rats Congenic at the Nat2 Locus 
Rapid and slow acetylator Nat2 congenic Fischer 344 (F344.WKY) rats 
were housed in the University of Louisville animal facility and the experiments 
were reviewed and approved by the University’s Institutional Animal Care and 
Use Committee. The construction of rapid and slow acetylator Nat2 congenic rats 
was previously reported [64]. Briefly, F344 (homozygous Nat2 rapid) males were 
mated to WKY (homozygous Nat2 slow) females to produce the obligate 
heterozygous F1 generation. F1 females were then backcrossed with F344 males. 
Heterozygous acetylator female progeny from each successive backcross were 
identified by rat Nat2 genotype and were mated with F344 rapid acetylator males. 
After ten generations of backcrossing, heterozygous acetylator brother/sister 
progeny were mated to produce the homozygous rapid and slow acetylator 
congenic rat Nat2 lines. The congenic F344.WKY rats have been confirmed for 
rapid and slow acetylator phenotype across multiple tissues and substrates [64]. 
 
Methylnitrosourea Administration 
Forty-two female rapid acetylator congenic rats and thirty-four female slow 
acetylator congenic rats, at 3 weeks of age, were administered methylnitrosourea 
(MNU; CAS#: 684-93-5)(Ash-Stevens, Detroit, MI) by a single intraperitoneal (IP) 
injection of 50 mg/kg (10 mg/ml) solution dissolved in saline pH 5.0, acidified with 
glacial acetic acid (figure 3.3) [98-100]. Six rapid and six slow acetylator control 
female rats were injected with vehicle. During the twenty-three week experiment, 
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one rapid (17 weeks) and two slow acetylator rats (18 and 18 weeks) were 
euthanized due to tumor burden and/or size. These data were incorporated into 
the statistical analysis.  
 
Twenty-four rapid acetylator female congenic rats and thirty-three slow 
acetylator female congenic rats, at 8 weeks of age, were administered MNU by a 
single IP injection of 50 mg/kg (10 mg/ml) as above (figure 3.3). Three rapid and 
four slow acetylator control female rats were injected with vehicle. During the 
study one rapid female acetylator rat was euthanized (16 weeks) because of 
tumor burden and/or size. This sample was included in the statistical analysis.  
 
7,12-dimethylbenzanthracene Administration 
Twenty-eight rapid acetylator female congenic rats and thirty-three slow 
acetylator female congenic rats were given a single dose of 7,12-
dimethylbenzanthracene dissolved in sesame seed oil (DMBA; CAS#: 57-97-
6)(Acros Organics, New Jersey, USA) (65 mg/kg) by oral gavage at 8 weeks of 
age (figure 3.3)[101, 102]. Three rapid and three slow acetylator control female 
rats were injected with vehicle. During the study four rapid female acetylator rats 
were euthanized (14, 17, 20, and 21 weeks) because of weight loss or tumor 
burden issues. Additionally six slow acetylator females were euthanized (9, 17, 
14, 20, 21, and 21 weeks) for weight loss or tumor burden issues. These data 





Figure 3.3. Experimental design for chemical-induced tumor experiments. Top 
shows the dosing of MNU at 3 weeks of age. The middle displays the dosing of 







Weekly Monitoring of Animal Weight and Palpable Mammary Tumors 
Rats were weighed weekly following carcinogen administration. Rats that 
displayed bradykinesia/fatigue, a tumor size = 10% of body weight, or tumors that 
were ulcerated (any break in skin observed) were euthanized. Rats were 
palpated weekly. The number of weeks post-carcinogen exposure of first 
palpable mammary tumor was recorded. 
 
Mammary Tissue and Tumor Collection 
Twenty-three weeks after administration of a carcinogen, rats were 
euthanized by CO2 asphyxiation followed by cervical dislocation. The rats were 
immediately dissected to count mammary tumors that were ≥3 mm in any 
direction, collect samples, and record any abnormalities. Mammary tumor and 




Tissue samples described above were processed and stained by the 
Special Procedure Laboratory at the University of Louisville. In brief, tissue was 
paraffin embedded and sections cut at 5 µm. Sections were stained using 
hematoxylin and eosin (H&E). H&E stained slides were evaluated and 
categorized, based on histomorphology, into the following groups: Normal, 
Benign, Low Grade Carcinoma In Situ (CIS), Intermediate Grade CIS, High 
Grade CIS and Invasive Carcinoma. If a mammary tumor demonstrated multiple 
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features of more than one category, the most malignant category was used for 
classification. Rats with multiple tumors were categorized by the most severe 
classification. These evaluations and classifications were performed blind to rat 
treatment and phenotype.  
 
Rapid and Slow Acetylator Rat NAT2 Recombinant Expression and 
Enzymatic Activity 
Recombinant rapid and slow acetylator rat NAT2 proteins were expressed 
in JM105 E. coli as described [56, 103]. Total bacterial lysate protein 
concentration was determined for each expression using the Bio-Rad protein 
assay kit (Bio-Rad, Hercules, CA). Bacterial lysates were assayed for N-
acetylation of para-aminobenzoic acid (PABA) and folate-dependent AcCoA 
hydrolysis.  
 
For determination of PABA N-acetylation activity, lysates (in triplicate) 
were incubated with 1 mM AcCoA and 300 µM PABA for 10 min at 37°C, and the 
reaction was stopped by addition of 1/10 volume of 1 M acetic acid. The reaction 
tubes were centrifuged to remove precipitated protein, and supernatant was 
injected onto a LiChrospher 100 RP-18 (125 mm X 4 mm; 5 µm) reverse-phase 
column. Reactants and products were separated by high-performance liquid 
chromatography (HPLC)(Beckman Coulter, Fullerton, CA). N-Acetyl-PABA 




Bacterial lysates were assayed for folate-dependent AcCoA hydrolytic 
activity as reported [103]. In brief, lysates (in triplicate) were incubated with 500 
µM AcCoA in the presence or absence of 300 µM folate for 10 min at 37°C, and 
the reaction was quenched by adding 1/10 volume of perchloric acid (15% w/v). 
The precipitated protein was removed by centrifugation and the supernatant was 
injected onto a C18 reverse-phase HPLC column (250 mm X 4 mm; 5 µm). 
Reactants and products were separated and quantitated by HPLC. Separation of 
CoA, acetyl CoA, and folate was achieved using a linear gradient of 100% 100% 
55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium phosphate 
pH 4.0: 100% methanol over 20 mins and was quantitated by absorbance at 260 
nm. The amounts of CoA produced in the minus folate reactions were subtracted 
from reactions containing folate to determine folate-dependent hydrolysis. 
Control reactions without the addition of protein lysate also were included. The 
limit of detection for CoA was 0.05 nmoles/min/mg protein. 
Rapid and Slow Congenic Rat Tissue Lysate Preparation and 
Enzymatic Activity 
Liver, lung, colon, and mammary tissues were collected from 8 week old 
female rapid and slow NAT2 congenic rats. Tissues were homogenized in 20 mM 
sodium phosphate (pH 7.4), 1 mM EDTA, 0.2% triton X-100, 1 mM dithiothreitol, 
100 µM phenylmethanesulfonyl fluoride, 10 µg/ml aprotinin, and 1 µM pepstatin. 
Homogenates were centrifuged at 15,000 x g for 10 min, and aliquots of 
supernatants were stored at -80°C until used. Protein concentrations were 
determined using the Bio-Rad protein assay kit. 
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To measure PABA N-acetylation activity, reactions containing tissue lysate 
(<2 mg of protein/ml), 300 µM PABA and 1 mM AcCoA were incubated at 37 °C 
for 10 min. Reactions were terminated by the addition of 1/10 volume of 1 M 
acetic acid. Activity was quantified by HPLC as described above.  
 
To measure folate-dependent AcCoA hydrolytic activity, reactions 
containing tissue lysate (<2 mg of protein/ml), 300 µM folate and 500 µM AcCoA 
were incubated at 37 °C for 10 min. Reactions were terminated by the addition of 
1/10 volume of perchloric acid (15% w/v). Activity was quantified by HPLC as 
described above.  
 
Rat Embryonic Fibroblasts Isolation  
Rat embryonic fibroblasts (REFs) were isolated from congenic rats by 
adapting procedures described previously for mouse embryonic fibroblasts [104]. 
Dams were euthanized by CO2 asphyxiation and cervical dislocation on E13.5 
(13.5 days post copulation) and embryos removed by Caesarean section. 
Embryonic brain tissue and organs were removed. The resultant tissue was 
dissociated by gentle enzymatic digestion [0.05% trypsin (w/v) for 15 mins] and 
cells were plated into 10 cm dishes (one embryo per dish) in DMEM (Dulbecco’s 
modified Eagle’s medium; high glucose, Lonza, Walkersville, MD, USA) 
supplemented with 10% FBS (fetal bovine serum), 2 mM L-glutamine, 100 
units/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin. 
Passaging was by cell dissociation from plates [0.05% trypsin (w/v) for 15 mins] 
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and re-plating 5 x 105 cells on fresh 10 cm dishes. Resulting REF cell lines at 
passage 4 were characterized for their PABA N-acetylation activities as 
described above.  
 
REFs Endogenous Cellular AcCoA Concentration Measurements 
Endogenous acetyl-CoA levels within REFs were determined by HPLC. 
On passage 4, the REFs were plated at 5 x 105 per 10 cm plate and allowed to 
grow for 96 hours. After 96 hours, media were aspirated from each plate, and 
washed with 5 ml phosphate-buffered saline (PBS). Then cells were gently 
dissociated from the plate with 0.5 ml trypsin [0.05% (w/v) for 15 min]. Cells were 
suspended in 4 ml of diluted complete media (20% medium and 80% PBS). 
Aliquots of 0.5 ml were used to count the number of cells per ml. In the 
subsequent steps all cells and lysates were kept on ice or in 4°C conditions. 
Collected cells were washed with ice cold PBS, and transferred to a 1.5 ml 
microcentrifuge tubes. The suspended cells were collected by centrifugation and 
the supernatants discarded. Having removed any residual PBS, the cells were 
lysed in 100 µl of ice-cold 5% 5-sulfosalicylic acid with a 1 ml BD Insulin Syringe 
with permanently attached 28 gauge needle (BD Franklin Lakes, NJ, USA). The 
cellular lysate was then centrifuged at 13,000 x g for 10 min. Supernatant was 
filtered through a syringe filter (13 mm, 0.20 µm pore size). Filtrate was collected 
and separated on a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µm 
pore size). HPLC separation and quantitation of AcCoA was achieved using the 




Weights were compared over time by a two-way analysis of variance 
followed by Bonferroni post hoc test. Latency and incidence of first palpable 
mammary tumors over time were tested by logrank (Mantel-Cox) test. Mann-
Whitney tests were used to compare mammary tumor multiplicity. Terminal tumor 
incidence was tested by a Fischer’s exact test. Enzymatic activities and 
endogenous AcCoA concentrations were compared by unpaired t-tests. All 
statistical tests were done using Prism software by GraphPad (La Jolla, CA). 
Data are displayed and presented as the average ± standard error of mean 






Rapid and slow acetylator congenic rats administered vehicle at either 3 or 
8 weeks demonstrated normal weight gain. Initially, all MNU-treated rats 
experienced hindered weight gain post administration, but then recovered to a 
rate of weight gain similar to vehicle-treated rats. MNU-treated rats never 
reached the same weight as the vehicle-treated counterparts (figure 3.4). No 
statistically significant (p>0.05) differences in weight gain were noted between 
MNU-treated rapid and slow acetylator congenic rats.  
 
DMBA-treated rats displayed no initial hindrance in weight gain; however, 
during the time following DMBA administration, DMBA-treated rats tended to 
have lower body weight than vehicle-treated rats (figure 3.4). No statistically 
significant (p>0.05) differences in weight gain were noted between DMBA-treated 






Figure 3.4. Weekly body mass (mean grams ± SEM) of rapid and slow acetylator 
Nat2 congenic rats post administration of specified carcinogen or vehicle control. 
In all three panels squares represent rapid acetylator and circles represent slow 
acetylator congenic rats. Filled-shapes represent vehicle-treated and unfilled-
shapes represent MNU or DMBA-treated. Weights for rats treated with MNU at 3 
weeks of age (A). The difference between weights of the vehicle-treated and 
MNU-treated is statistically significant by two-way ANOVA with Bonferroni post 
hoc test (p<0.05). Weights for rats treated with MNU at 8 weeks of age (B). The 
weights of the vehicle-treated and MNU-treated rats were statistically significant 
by two-way ANOVA with Bonferroni post hoc test (p<0.05). Weights for rats 
administrated DMBA at 8 weeks of age (C). The weights of the vehicle-treated 
and DMBA-treated rats were not statistically significant by two-way ANOVA with 
Bonferroni post hoc test (p>0.05). In all panels, weights of MNU/DMBA-treated 





Palpable Mammary Tumor Latency and Incidence 
As shown in figure 3.5, rapid acetylator congenic rats had significantly 
shorter latency for development of their first palpable mammary tumor compared 
to slow acetylator NAT2 congenic rats after administration of MNU in females 
treated at either 3 or 8 weeks of age. Rapid acetylator rats showed significantly 
higher tumor incidence compared to slow acetylator rats after MNU 
administration at 3 or 8 weeks of age. 
 
DMBA-treated rapid acetylator rats displayed a higher tumor incidence 
over the course of the treatment than DMBA-treated slow acetylator rats, 
although logrank test analysis provides a p-value (p=0.065) slightly greater than 
our established p-value threshold of significance (p=0.050). 
 
Terminal Mammary Tumor Incidence and Multiplicity 
As shown in table 3.1, female congenic rats, administered MNU at 3 
weeks of age, developed tumors in 66.7% of the rapid acetylator congenic rats 
with an average 1.00 ± 0.17 tumors per rat. In contrast, tumors were found in 
52.9% of slow acetylator congenic rats with an average of 0.67 ± 0.12 tumors per 
rat. These mammary tumor incidence and multiplicity results were not 
significantly different between rapid and slow acetylator rats administered MNU 






Figure 3.5. Kaplan-Meier plot of palpable mammary tumors in congenic rats. 
Onset of tumors in rats exposed to MNU at 3 weeks of age (A), MNU at 8 weeks 
of age (B), and DMBA at 8 weeks of age (C). Squares illustrate rapid and circles 
illustrate slow acetylator Nat2 congenic rats. Rapid acetylator congenic rats had 
a significantly (p<0.05) shorter latency for development of first palpable 
mammary tumor compared to slow acetylator congenic rats after MNU 
administration at either 3 or 8 weeks of age. Similar findings were obtained after 





As shown in table 3.1, female congenic rats administered MNU at 8 weeks 
of age developed tumors in 41.6% of rapid acetylators with 0.50 ± 0.14 average 
tumors per rat. Slow acetylators developed tumors in 15.2% of those given MNU, 
with 0.24 ± 0.12 tumors per rat. Thus, rapid acetylator rats exhibited significantly 
higher mammary tumor incidence (p=0.035) and multiplicity (p=0.050) compared 
to slow acetylator rats.  
 
No other tissue/organ tumors besides mammary tumors were observed in 
either MNU- or vehicle-treated rats. A few rats displayed discoloration of the 
eyes, thought to be an onset of cataracts. Cataracts and retinal degradation can 
occur in rats following MNU administration [105].  
 
As shown in table 3.1, female congenic rats exposed to DMBA developed 
mammary tumors in 76.0% of rapid acetylators with 1.20 ± 0.16 average tumors 
per rat. Slow acetylators developed tumors in 43.3% of those given DMBA, with 
0.57 ± 0.14 tumors per rat. Rapid acetylator rats had significantly higher 
mammary tumor incidence (p=0.027) and multiplicity (p=0.004) compared to slow 
acetylator rats. No other tissue/organ tumors besides mammary tumors were 





















Total tumors per rat in 
tumor- bearing ratsc 
MNU 
3 weeks Rapid 42 28 (66.7%) 42 1.00 ± 0.17 1.50 ± 0.20 
MNU 
3 weeks Slow 34 18 (52.9%) 23 0.67 ± 0.12 1.28 ± 0.11 
MNU 
8 weeks Rapid 24 10 (41.6%)* 12 0.50 ± 0.14* 1.20 ± 0.20 
MNU 
8 weeks Slow 33 5 (15.2%)* 8 0.24 ± 0.12* 1.60 ± 0.24 
DMBA 
8 weeks Rapid 25 19 (76.0%)* 30 1.20 ± 0.16** 1.58 ± 0.12 
DMBA 




bTumor multiplicity  
 





A majority of the mammary tumors that developed in carcinogen-treated 
rats were classified as non-invasive (figure 3.6). More tumors classified as 
benign were noted in rats administered MNU at 3 weeks compared to 8 weeks of 
age (15% and 0%, respectively).  
 
Among the rapid and slow congenic rat strains administrated MNU at 3 
weeks of age, ~11% of tumors were classified as invasive carcinomas in the 
rapid acetylators (3/28) versus none in the slow acetylators (0/18). Low grade 
CIS tumors were the most common histomorphological classification of tumors in 
both rapid and slow rat Nat2 congenic strains.  
 
Rats administered MNU at 8 weeks of age exhibited similar percentages 
of mammary tumors classified as low grade CIS in rapid (5/10) and slow (2/5) 
acetylators. Mammary tumors classified as high grade CIS tumors were 
observed in 3 rapid acetylator congenic rats (3/10), and the only tumor classified 
as invasive was found in one slow acetylator rat (1/5).  
 
In general, rats administered DMBA displayed a very similar distribution 
pattern of tumor pathology. The rapid NAT2 congenic rats had more benign 
tumors (4/19 or 21%) than slow NAT2 congenic rats (1/13 or 8%). The slow 
congenic rats had a higher percentage of tumors with an invasive classification 







Figure 3.6. Photomicrographs of H&E stained slides depicting the criteria utilized 
to classify tumors. Normal mammary tissue (a). Benign tumor (b) showing 
proliferative disease with no cytologic atypia and minimal to no overgrowth of the 
epithelial or myoepithelial component (black arrows). CIS lesions (c-e) with 
overgrowth of the epithelial and/or myoepithelial component (red arrows). Low 
grade CIS lesion (c) with low grade cytologic atypia and occasional mitoses or 
single cell apoptosis. Intermediate grade CIS lesion (d) with intermediate to high 
grade cytologic atypia with increased mitoses (blue arrows) or single cell 
apoptosis. High grade CIS lesion (e) with intermediate to high grade cytologic 
atypia with tumor necrosis (yellow dashed arrow) and increased mitoses (blue 






Enzymatic Activities of Recombinant Rapid and Slow Rat NAT2  
PABA N-acetylation velocities for rat arylamine N-acetyltransferase 2 
catalyzed by recombinant rapid acetylator NAT2 was significantly (p=0.005) 
higher than by recombinant slow acetylator NAT2 (figure 3.7A). The folate-
dependent AcCoA hydrolysis catalyzed by rat NAT2 was significantly (p=0.005) 
higher for recombinant rapid acetylator NAT2 than recombinant slow acetylator 
NAT2 (figure 3.7B).  
 
Rapid and Slow Acetylator Rat NAT2 Activities in Tissue Lysates 
The PABA N-acetylation activities of Nat2 congenic rats measured in 
lysates from several tissue-types was significantly higher in rapid than slow 
acetylators: liver (p<0.001), lung (p<0.001), colon (p=0.007), and mammary 
gland (p<0.001) (figure 3.7C). The folate-dependent AcCoA hydrolysis was 
significantly higher in rapid acetylator than slow acetylator lung (p=0.002) and 
colon (p=0.002) (figure 3.7D). No detectable folate-dependent AcCoA hydrolysis 
activity was observed in liver and mammary tissue lysates (threshold of detection 








Figure 3.7. Rat NAT2 PABA acetylation (A, C) and folate-dependent AcCoA 
hydrolysis activity (B,D). The same recombinant lysates were used in triplicate for 
each activity (A, B).. Lysates of individual tissues collected from either 5 rapid 
(closed bars) or 5 slow (open bars) acetylator NAT2 F344 congenic rats (C, D). 
“ND” = not detectable. The number of asterisks corresponds to the p-value: *** = 





NAT2 Activity and Endogenous AcCoA Concentrations in Isolated 
Congenic REFs 
The REFs isolated from the congenic rat strains were characterized for 
their ability to acetylate PABA and their endogenous AcCoA concentrations after 
the fourth passage. PABA N-acetylation in rapid NAT2 REFs was significantly 
higher than in slow NAT2 REFs (p=0.002) (figure 3.8A). Endogenous AcCoA 
concentrations levels in the rapid NAT2 REFs were lower compared to that of the 














Figure 3.8. NAT2 activity and AcCoA level measured in rat embryonic fibroblasts 
(REFs) from rapid and slow rats. Rapid NAT2 REFs (N=7) have a higher level of 
PABA acetylation activity than slow NAT2 REFs (N=9) (A). The amount of AcCoA 
per million cells is lower in rapid NAT2 REFs (N=8) than in slow NAT2 REFs 




This study is the first to utilize a functional animal model to look at 
tumorigenic differences between rapid and slow rat NAT2 activity using 
carcinogens that do not require NAT2 activity for activation/deactivation. This 
functional animal model mimics human populations. Rat NAT2 is the ortholog of 
human NAT1. Genetic variants and other factors influence human NAT1 activity 
levels. The NAT1*10 haplotype is associated with increased NAT1 activity in 
human tissue samples [26-28]. Other polymorphic haplotypes encode a less 
stable NAT1, leading to a decrease in enzymatic activity. Our results in Nat2 
congenic rats suggest that human genetic variation resulting in differential NAT1 
activity may influence human breast cancer. Furthermore, our findings suggest 
that NAT1*10 human haplotypes may have a higher risk of breast cancer 
compared to the reference NAT1*4 haplotype. Also, polymorphic variants that 
decrease NAT1 activity would likely have a reduced cancer risk.  
 
In the present study, we investigated whether chemical carcinogens 
induced tumors more rapidly or in greater abundance in rapid than slow Nat2 
congenic rat strains. MNU was administered at either a pre-pubescent age (3 
weeks) or a post-pubescent age (8 weeks). Additionally DMBA was administered 
at only post-pubescent age (8 weeks). We observed decreased latency and 
increased incidence of palpable mammary tumors in congenic rapid acetylator 
rats than in congenic slow acetylator rats treated with either MNU or DMBA. 
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Terminal multiplicity and incidence also were higher in rapid than slow acetylator 
rats administered MNU or DMBA.  
 
The role of human NAT1 in cancer is not well understood, but the current 
understanding of NAT1’s potential importance in cancer is expanding. Several 
microarray studies have shown that elevated NAT1 expression is correlated with 
estrogen receptor positive (ER+) breast cancer samples [8, 10, 16]. Human 
NAT1 expression in breast cancer is predicted to be a valuable indicator for 
antiestrogen responsiveness [106] and an indicator of a positive prognosis, 
particularly in ER+ breast cancer [107]. Normal human mammary luminal 
epithelial cell lines (HB4a) engineered to overexpress NAT1 continue growing 
compared to normal HB4a cells that reach a growth plateau [8]. The present 
study adds to the developing and complex narrative of NAT1 in cancer, by 
providing the first animal model data that show an association between NAT1 
activity levels and tumorigenesis independent of carcinogen metabolism. 
 
Rapid acetylator rats displayed elevated risk of mammary tumors 
compared to slow acetylator MNU-treated rats regardless of whether treatment 
occurred when immature or mature. Pre-pubescent exposure to MNU, regardless 
of NAT2 activity phenotype, resulted in greater palpable tumor incidence, as well 
as increased terminal mammary tumor incidence and multiplicity (table 3.1 and 
compare panels in figure 3.5). This increase with earlier age of MNU-exposure is 
consistent with the known elevated breast cancer susceptibility of prepubescent 
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female breasts to cancer induced by ionizing radiation [108]. MNU, a simple 
alkylating agent, is radiomimetic [109]. Humans are exposed to alkylating 
chemical carcinogens in diet, tobacco products, cosmetics, drugs, and 
chemotherapy [110]. The results reported in the current study suggest that the 
human NAT1 (an ortholog of rat NAT2) phenotype and prepubescent carcinogen 
exposure should be studied as additional factors in human breast cancer 
susceptibility.  
 
The role rat NAT2 activity plays in increased tumorigenesis is poorly 
understood. Our hypothesis is that a more active rat NAT2 might lower vital 
compounds needed for DNA repair to a greater extent than a less active rat 
NAT2. Rat NAT2 and human NAT1 are orthologous enzymes that, in addition to 
their acetylation capacity, catalyze the hydrolysis of AcCoA to acetate and 
coenzyme A in the presence of folate [54, 103]. Thus, rapid rat NAT2 (or more 
active human NAT1) can reduce intracellular levels of AcCoA to a greater extent 
than slow rat NAT2, affecting crucial pathways supporting DNA repair (e.g. 
histone and p53 acetylation). In support of this hypothesis, measurement of 
NAT2 activity in rapid acetylator rat tissues showed higher levels of PABA N-
acetylation and folate-dependent AcCoA hydrolysis than in slow acetylator rat 
tissues. These differences were also reflected in recombinant rapid and slow 
acetylator NAT2 expressed in bacteria. As shown with congenic rat tissues and 
recombinant NAT2 proteins, REFs isolated from rapid NAT2 rats had a higher 
PABA N-acetylation activity level than REFs isolated from the slow NAT2 
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congenic rats. Furthermore, rapid NAT2 REFs had lower levels of AcCoA 
compared to the slow NAT2 REFs. This observation parallels the findings with 
folate-dependent AcCoA hydrolysis, in that rapid acetylator NAT2 is able to 
hydrolyze AcCoA at greater rates than slow acetylator NAT2 and thus more likely 
to reduce endogenous AcCoA levels. 
 
The study of intracellular AcCoA concentration levels has not been well 
characterized after DNA insult. Some studies have shown AcCoA concentrations 
control cell growth, cellular autophagy, and histone acetylation [111-113]. Other 
studies have shown reduced acetylation of downstream targets if acetyl-CoA 
carboxylase, ATP-citrate lyase, or pantothenate kinase are knocked out [113-
115]. Future studies will further explore human NAT1 activity in relation to 
intracellular AcCoA concentrations and associated differences in acetylation 
targets. As shown in Chapters 4 and 5, human NAT1 knockdown and knockout 
cancer cell lines have elevated AcCoA concentrations compared to their wildtype 
counterparts. 
 
Breast cancer is one of the most common types of cancer. It is estimated 
that in 2016 breast cancer will be the most diagnosed type of cancer in United 
States women, excluding basal and squamous cell skin cancers [116]. It is also 
expected that breast cancer will be one of the leading causes of death from 
cancer in women, with only lung cancer ranking higher [116]. Breast cancer’s 
persistence as one of the most formidable cancers in women illuminates the 
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need to understand differences in cancer susceptibility and discover novel 
avenues for prevention and treatment. The studies in this chapter primarily focus 
on breast cancer. However given ubiquitous expression of NAT1, the findings 
here are likely to be observed in other cancer sites such as lung, colon, urinary 





INHIBITION OF ARYLAMINE N-ACETYLTRANSFERASE 1 REDUCES 




Arylamine N-acetyltransferase 1 (NAT1) historically is identified as a 
phase II drug and carcinogen metabolizing enzyme which catalyzes the transfer 
of an acetyl group from acetyl-coenzyme A (AcCoA) to the amine nitrogen of 
arylamine and hydrazine compounds. Recently, human NAT1 has been shown to 
catalyze hydrolysis of AcCoA in the presence of folate [54, 103].  
 
NAT1 expression is elevated in invasive and lobular breast carcinomas 
when compared to normal breast tissue [8]. This overexpression of NAT1 was 
confirmed at the mRNA level and by immunohistological analysis in 108 breast 
cancer samples that demonstrated a strong association of NAT1 staining and 
estrogen receptor-positive tumors [8]. Elevated NAT1 expression in estrogen 
receptor-positive tumors has been observed in multiple studies [20, 67]. Also, 
elevated NAT1 expression is associated with breast cancer bone metastasis [24, 
117]. Adam et al. demonstrated that overexpression of NAT1 in a normal luminal 
epithelial-derived cell line conferred enhanced growth properties and etoposide 
	
	 62	
resistance compared to control cells that had been transfected with an empty 
vector [8]. Subsequent studies demonstrated that a small molecule inhibitor of 
NAT1 activity caused decreased cell growth and reduced ability of MDA-MB-231 
human breast cancer cells to grow in soft agar [11]. A lentiviral-based NAT1 
shRNA, which reduced NAT1 activity by 74%, reduced cell invasion by 50% in 
MDA-MB-231 human breast cancer cells [11]. NAT1 activity is cell-cycle phase-
dependent showing an association between high NAT1 activity and accelerated 
progression through the cell cycle in HaCaT keratinocytes [118]. Tiang et al. 
showed in the colon cancer cell line HT-29 that RNAi mediated knockdown of 
NAT1 by approximately 85% led to increased cell-cell contact inhibition, loss of 
cell viability at confluence, and attenuation of anchorage-independent cell growth 
[13]. Overall these previous studies have shown a relationship between NAT1 
activity and cancer cell proliferation, anchorage-independent growth abilities, and 
invasiveness.  
 
Human NAT1 activity is modified by polymorphism, but can also be 
regulated by microRNA, epigenetic, and/or translational and post-translational 
control features [67-70]. NAT1 transcript levels can be regulated by extracellular 
stimuli acting on glucocorticoid or androgen receptors [71, 72]. Exposure to 
NAT1 substrates can increase NAT1 degradation, which results in decreased 
NAT1 activity [69, 70]. Oxidative stress can reversibly or irreversibly inactivate 
NAT1 [119, 120]. NAT1 inhibitors have been reported including cisplatin [121], 
curcumin [122, 123], disulfiram [124], and rhodanine derivatives [125, 126]. The 
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ability to control the level of NAT1 activity and expression by various means may 
reduce cancer growth or metastasis. 
 
To better understand how variation in NAT1 activity can affect cancer cell 
growth and invasion properties, we utilized RNAi technology and a small 
molecule inhibitor of NAT1 in the human breast cancer cell line MDA-MB-231. 
We used the Sure SilencingTM shRNA plasmid described previously [13], and a 
rhodanine derivative (5E)-[5-(4-hydroxy-3,5-diiodobenzylidene)-2-thioxo-1,3-





MATERIALS AND METHODS 
 
Cell Line Generation and Culturing Conditions  
The breast adenocarcinoma cell line, MDA-MB-231, was purchased from 
ATCC (Manassas, Virginia). Cells were cultured in DMEM media, high glucose 
with the addition of fetal bovine serum to 10% and glutamine to 2 mM. 
SureSilencingTM Predesigned shRNA and NAT1 knockdown shRNA plasmids 
were purchased from SA Biosciences. Initial screening found that the NAT1 
shRNA Clone 1 reduced NAT1 catalytic activity by 29% while NAT1 shRNA 
Clone 3 reduced NAT1 catalytic activity by 50%. Further studies were conducted 
with NAT1 shRNA Clone 3 because it was used in previous experiments [10] and 
resulted in the greatest reduction in NAT1 expression. The shRNA sequence for 
the scrambled shRNA and NAT1 shRNA clone 3 were transferred from the 
pGeneclipTM vector to the pcDNA5/FRT vector. The NAT1 overexpression 
plasmid NATb/NAT1*4 in pcDNA5/FRT was previously described [127].  
 
A MDA-MB-231 breast cancer cell line with a single FRT site was 
constructed using the Flp-In System (Life Technologies, Grand Island, NY) as 
described previously [128]. Once an MDA-MB-231 cell line was constructed with 
a single FRT site in a transcriptionally active region, we transfected the shRNA 
plasmids and the NAT1 overexpression plasmid to deliver the cassettes to the 
same genetic location. The pcDNA5/FRT plasmids containing the scrambled 
shRNA, NAT1 specific shRNA plasmid or the NAT1 overexpression plasmid 
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NATb/NAT1*4 [127] were co-transfected with pOG44 (Life Technologies), a Flp 
recombinase expression plasmid, using Amaxa Cell Line Nucleofector Kit V 
(Lonza, Basel, Switzerland) following the manufacturer’s recommendations. 
Since the pcDNA5/FRT vector contains a hygromycin resistance cassette, cells 
were passaged in complete DMEM containing 500 µg/ml hygromycin to select for 
cells with the pcDNA5/FRT plasmid stably integrated into their genomic DNA. 
Hygromycin-resistant colonies were selected approximately 2 weeks after 
transfection and isolated using cloning cylinders. Unless otherwise stated 
experiments using cell lines were performed with cells in log phase of growth. 
 
In summary, the following MDA-MB-231 cell lines were constructed: 
1. Scrambled shRNA cell line stably transfected with scrambled 
shRNA as a control cell line to which other cell lines are compared.  
2. NAT1 knockdown cell line stably transfected with NAT1 
specific shRNA. 
3. NAT1 overexpression cell line stably transfected with the 
NATb/NAT1*4 cassette. 
 
In Vitro and In Situ NAT1 N-acetyltransferase Assays for Cell Lines  
In vitro assays using the NAT1 selective substrate para-aminobenzoic 
acid (PABA) were conducted and the N-acetyl-PABA product was separated and 
quantitated as described [129]. Briefly, cells were scraped from the plate, washed 
in 1X phosphate-buffered saline (PBS), and lysed in 20 mM sodium phosphate 
	
	 66	
pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.2% triton X-100,, 1 mM 
dithiothreitol (DTT), 100 µM phenylmethanesulfonyl fluoride (PMSF), 1 µg/ml 
aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10 
min and supernatant tested for NAT1 activity. Enzymatic reactions containing 50 
µL suitably diluted cell lysate, PABA (300 µM) and acetyl coenzyme A (1 mM) 
were incubated at 37°C for 10 min. Reactions were terminated by the addition of 
1/10 total reaction volume of 1 M acetic acid and centrifuged at 15,000 X g for 10 
min. Three independent measurements (N=3) performed in triplicate were 
completed for each cell line. 
 
Measurement of N-acetylation in situ was determined by spiking media 
with a known concentration of PABA as described [130]. The cells were 
incubated at 37°C for 48 h with media containing 500 µM PABA. Media were 
collected and 1/10 total collected media volume of 1 M acetic acid was added. 
The acidified media were centrifuged at 15,000 X g for 10 min. There were four 
independent measurements (N=4) performed in triplicate for each cell line.  
 
Resulting supernatants from in vitro and in situ NAT1 activity assays was 
injected into a reverse phase C18 column (125 mm × 4 mm; 5 µM pore size). 
Reactants and products were eluted using a Beckman System Gold high 
performance liquid chromatography (HPLC) system. HPLC separation of N-
acetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 2.5: 
acetonitrile at 280 nm. The data for scrambled shRNA, knockdown and 
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overexpression cell lines are represented as mean ± SEM and analyzed 
statistically by a one-way ANOVA and Bonferroni post- test. 
 
Endogenous Cellular Acetyl-Coenzyme A (AcCoA) Levels for Cell 
Lines 
Endogenous AcCoA levels within modified MDA-MB-231 cancer cell lines 
(scrambled shRNA, knockdown, and overexpression) were determined by HPLC. 
Cell growth conditions were strictly monitored because it was observed that 
cellular confluence and period of growth affected the consistency of data 
obtained for the endogenous AcCoA concentrations. Cells were plated at 1 x 106 
per 10 cm plate (3 plates per N) with fresh complete culturing media with no 
selection antibiotic added, and allowed to grow for 72 h. After 72 h, the cells were 
70% confluent and collected. Media were aspirated from the plates, and each 
plate was washed with 5 ml PBS. Then cells were dissociated from the plate with 
0.5 ml trypsin [0.25% (w/v)]. Cells were suspended in 4 ml of diluted complete 
media (20% medium and 80% PBS) and counted in 0.5 ml aliquots. In the 
subsequent steps all cells and lysates were kept on ice or at 4°C. Collected cells 
were centrifuged, supernatant removed, and ice-cold PBS was added. Again, 
cells were centrifuged, supernatant removed, suspended in 1 ml of ice-cold PBS, 
and transferred to 1.5 ml microcentrifuge tubes. The suspended cells were 
collected by centrifugation and the supernatants discarded. Having removed any 
residual PBS, the cells were lysed in 100 µL ice-cold 5% 5-sulfosalicylic acid with 
a 1 ml BD Insulin Syringe with permanently attached 28 gauge needle (BD 
	
	 68	
Franklin Lakes, NJ, USA). The needle selection is important to insure complete 
cell lysis without loss of volume or cellular masses within the syringe/needle. The 
cellular lysate was then centrifuged at 13,000 x g for 10 min. Supernatant was 
filtered through a syringe filter (13 mm, 0.20 µm pore size). Filtrate was collected 
and separated on a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µm 
pore size). HPLC separation and quantitation of AcCoA was achieved using a 
linear gradient of 100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 
mM sodium phosphate pH 4.0: 100% methanol over 20 min and was quantitated 
by absorbance at 260 nm. The data for individual determinations of scrambled 
shRNA, knockdown and overexpression cell lines (N= 8, 7, and 7 respectively) 
are represented as mean ± SEM, and were analyzed by a one-way ANOVA and 
Bonferroni post-test. 
Quantitation of NAT1 mRNA Levels  
NAT1 mRNA levels were measured as described previously [130]. Briefly, 
total RNA was isolated from the constructed MDA-MB-231 cell lines using the 
RNeasy Mini kit (Qiagen, Germantown, MD) following manufacturer’s 
instructions. cDNA was made using the High Capacity Reverse Transcriptase kit 
(Life Technologies) following manufacturer’s instructions. mRNA was quantitated 
via Real-time PCR using Taqman primers and probe (Life Technologies) 5’-
gaattcaagccaggaagaagca-3’ 5’tccaagtccaatttgttcctagact-3’ FAM-5’-
caatctgtcttctggattaa3’-MGB and PCR conditions suggested by the manufacturer. 
The data for scrambled shRNA, knockdown and overexpression cell lines are 
represented as mean ± SEM from three separate determinations performed in 
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triplicate (N=3), and were analyzed statistically by a one-way ANOVA and 
Bonferroni post-test. 
Determination of Doubling Time of Cell Lines 
Twenty-five thousand cells were plated in triplicate in 6-well plates and 
allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed 
to equilibrate for 24 h before making the first count on day 2 followed by counts 
on days 3, 4, 5 and 6 using a cell counter. A cell doubling rate was calculated for 
each day using Equation 1 (shown below) and then rates were averaged over the 
5 day time period to get a final cell doubling rate.  
Equation 1: Cell Doubling Rate = 1/(((log b − log (a))×3.32)/(t! − t!)) 
In the equation, b = cell number on day n, a = cell number on day n-1, t! = 
hours passed since plating when cells were counted on day n, and t! = hours 
passed since plating when cells were counted on day n-1. This assay was 
performed in triplicate for each cell line (N=3). The data for the cell lines are 
represented as mean ± SEM from three separate determinations performed in 
triplicate, and were analyzed statistically by a one-way ANOVA and Bonferroni 
post-test. 
 
Measuring the Effect of a Small Molecule Inhibitor on In Situ NAT1 
Activity and Cell Growth  
The ability of the small molecule inhibitor (5E)-[5-(4-hydroxy-3,5-
diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one] (5-HDST, CAS# 336171-85-8) 
(Ryan Scientific, Mount Pleasant, SC) to inhibit NAT1 activity was measured in 
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situ and its effects on cell growth measured as a percentage of untreated cells. 
Scrambled shRNA MDA-MB-231 cells were incubated with a single dose of 5-
HDST (ranging from 0-87.5 µM) for up to 6 days. Briefly, all cells were plated on 
day 0 and the varying concentrations of 5-HDST were added to the respective 
cells on day 1. Cells were plated in 12-well plates so that every successive day 
would have roughly the same number of cells to enable accurate measurement 
of PABA N-acetylation in situ and cell number. PABA (10 µM) was added to the 
media and incubated with the cells and 5-HDST for 24 h prior to measurements. 
After 24 h, media were removed from the cells and amounts of PABA and N- 
acetyl-PABA were measured by HPLC as described above. Cells were washed 
once with 1X PBS, scraped off the plate and counted using a cell counter. Three 
separate determinations performed in triplicate for PABA N-acetylation and cell 
number were carried out every 24 h for 6 days (N=3). The in situ NAT1 data, 
represented as means ± SEM, were analyzed statistically by a one-way ANOVA 
and Bonferroni post-test on day 6. The cell number data, represented as means 
± SEM, were analyzed statistically by a two-way ANOVA and Bonferroni post- 
test.  
 
Anchorage-Dependent and Anchorage-Independent Growth Assays  
Anchorage-dependent growth assays were performed by plating cells (300 
cells/well) in triplicate in 6-well plates and allowing them to grow for 2 weeks 
(N=3). For small molecule NAT1 inhibitor assays, 5-HDST (ranging from 0 to 
87.5 µM) was added to triplicate wells at the time of plating (N=3). Colonies were 
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counted following staining with crystal violet. The data are represented as means 
± SEM from three separate determinations performed in triplicate and were 
analyzed statistically by a one-way ANOVA and Bonferroni post-test. 
The anchorage-independent growth assays were performed by plating the 
cells in low-melting temperature agarose. The cells were grown in normal growth 
media where the bottom layer was 1.5 ml (noble agar, 0.5%) and the top layer 
was 1.5 ml (low-melting temperature agarose, 0.3%), so the total volume was 3 
ml in each well of a 6 well plate. Cells (6000 cells/well) were plated in triplicate in 
6-well plates and grown for 2 weeks. Colonies were counted following staining 
with crystal violet. For the anchorage-independent growth assay investigating 
effect of the small molecule NAT1 inhibitor, 5-HDST (ranging from 0 to 87.5 µM) 
was added at the time of plating of the cells. Three separate determinations 
performed in triplicate were completed for each assay (N=3). The data are 
represented as means ± SEM and were analyzed statistically by a one-way 
ANOVA and Bonferroni post- test. 
 
Transwell Assays to Assess Relative Invasive Ability  
Transwell assays were performed by depositing 1 X 105 cells in 100 µL of 
DMEM containing 0.2% FBS in the top chamber of the transwell and 600 µL of 
complete media in the bottom chamber. 5-HDST (ranging from 0 to 100 µM) was 
added to media on both sides of the membrane. Cells were allowed to invade 
across a membrane of Matrigel (Life Technologies). After 24 h, cells on the top 
side of the membrane were removed with a sterile cotton swab. Cells that 
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invaded across the membrane were quantified using the Alamar Blue cell 
quantitation assay. Three separate determinations performed in triplicate were 
made (N=3). The data are represented as means ± SEM, and were analyzed 






NAT1 Catalytic Activity, Endogenous AcCoA Levels, and mRNA 
Expression 
The stable partial knockdown of NAT1 reduced in vitro PABA NAT1 N-
acetylation to 61% of the scrambled shRNA cell line (figure 4.1A) and in situ 
PABA N-acetylation to 62% of the scrambled shRNA cell line (figure 4.1B). 
Stable overexpression of NAT1 increased the N-acetylation of PABA in vitro and 
in situ by 12-and 11-fold, respectively, compared to the scrambled shRNA cell 
line (figure 4.1 A&B). The partial knockdown of NAT1 in NAT1 shRNA 
knockdown MDA-MB-231 breast cancer cells increased endogenous AcCoA 
levels about 35% compared to the scrambled shRNA cell line (p<0.005) (figure 
4.1C). Endogenous AcCoA levels in the NAT1 overexpression MDA-MB-231 cell 
line did not differ significantly (p>0.05) compared to the scrambled shRNA cell 
line but were significantly below the AcCoA levels of the partial NAT1 knockdown 
cell line (p<0.05) (figure 4.1C). NAT1 mRNA expression in the stable knockdown 
was 47% of the scrambled shRNA cell line, and was 31-fold higher than the 









Figure 4.1. NAT1 catalytic activity and mRNA expression in stably modified 
MDA-MB-231 cell lines. Each bar illustrates mean ± SEM. The in vitro PABA N-
acetylation activity (A) in cell line lysates (N=3). The in situ PABA N-acetylation 
(B) in cell lines cultured in PABA spiked media (N=4). The endogenous AcCoA 
levels (C) for scrambled shRNA (N=8), NAT1 shRNA knockdown (N=7), and 
NAT1 overexpression (N= 7). NAT1 mRNA levels (D) in cell lines normalized to 
scrambled shRNA cell line (N=3). Differences between cell lines were 
significantly different (* p≤ 0.05; *** p≤ 0.001) following one-way ANOVA with a 







The doubling times for the scrambled shRNA cell line, NAT1 knockdown 
cell line and NAT1 overexpression cell line were 27.4, 27.2 and 23.4 hours 
respectively (figure 4.2A). Neither the knockdown nor overexpression of NAT1 
significantly (p=0.26) affected the doubling time compared to the scrambled cell 
line.  
 
Anchorage-Dependent Cell Growth, Anchorage-Independent Cell 
Growth, and Relative Invasive Ability 
Neither the knockdown nor overexpression of NAT1 significantly affected 
anchorage-dependent growth (figure 4.2B). However, the knockdown of NAT1 
caused a significant 7-fold decrease (p<0.0001) in anchorage-independent 
growth, whereas the overexpression of NAT1 had no significant effect (figure 
4.2C). Neither knockdown of NAT1 with shRNA nor overexpression of NAT1 had 








Figure 4.2. Cell growth properties in shRNA NAT1 knockdown and 
overexpression stably modified MDA-MB-231 cell lines. Each bar illustrates 
mean ± SEM. Cell doubling times (A) in the scrambled shRNA, NAT1 knockdown 
and NAT1 overexpression cell lines did not differ significantly following one-way 
ANOVA (p>0.05) (N=3). The anchorage-dependent growth (B) did not differ 
significantly among the scrambled shRNA, NAT1 knockdown and NAT1 
overexpression cell lines following one-way ANOVA (p>0.05) (N=3). The NAT1 
knockdown cell line formed significantly less anchorage-independent colonies (C) 
compared to scrambled shRNA and NAT1 overexpressing cell lines following 
one-way ANOVA followed by a Bonferroni post-test (*** p≤ 0.001) (N=3). No 
significant differences in relative invasion ability (D) among the scrambled 
shRNA, NAT1 knockdown and NAT1 overexpression cell lines were observed 




Effects of Small Molecule NAT1 Inhibitor on MDA-MB-231 Breast 
Cancer Cells 
To demonstrate that the effects of NAT1 knockdown on cell growth and 
invasion ability were due to reduced NAT1 activity, we tested the effects of a 
small molecule inhibitor of NAT1 that does not depend on decreased NAT1 
expression for reduced NAT1 catalytic activity.  
 
N-acetylation In Situ 
5-HDST (figure 4.3A) reduced PABA N-acetylation in situ in a 
concentration-dependent manner (p<0.0001)(figure 4.3B). A single dose of 5-
HDST reduced PABA N-acetylation in situ for at least 6-days (figure 4.3B). The 




Cells exposed to concentrations of 5-HDST ranging from 0 to 50 µM over 
a period of up to 6 days produced no significant effects on cell growth (figure 
4.4A). Concentrations of 5-HDST greater than 50 µM caused a concentration- 






Anchorage-Dependent and -Independent Cell Growth, and Relative 
Invasive Ability 
Incubation with 5-HDST reduced anchorage-dependent cell growth, but 
the effect was marginal below 50 µM (figure 4.4B). Incubation with 5-HDST 
markedly reduced anchorage-independent cell growth at 12.5 µM (figure 4.4C). 
Incubation with 5-HDST had no effect on relative invasion ability until 










Figure 4.3. Effects of a small molecular inhibitor (5-HDST) on NAT1 activity. 
Chemical structure of 5-HDST (A). The percentage of NAT1 activity remaining 
after incubation with 0 to 87.5 µM 5-HDST (B) for 1-6 days (N=3). 5-HSDT 
inhibition of NAT1 activity curve (C) used to calculate the IC50 for 5-HSDT 










Figure 4.4. Cell growth properties of MDA-MB-231 cells incubated with 5-HDST. 
Bars/symbols represent means ± SEM from three separate determinations 
performed in triplicate (N=3). Cell number (percent of vehicle) measured after 
incubation (1-6 days) with 5-HDST (A). Anchorage-dependent colongy formation 
following incubation with 5-HDST after 14 days (B). Anchorage-independent 
colony formation following incubation with 5-HDST after 14 days (C). Transwell 
assays to measure migratory ability of scrambled shRNA cell line incubated with 
5-HDST (D). One-way ANOVA was conducted to compare relative invasion 
ability between groups (p<0.05). The scrambled shRNA cell line incubated with 
100 µM 5-HDST had significantly (p<0.05) less invasion ability compared to 
scrambled shRNA cell line incubated with vehicle following one-way ANOVA and 







Understanding how heterogeneity in gene expression affects cancer cell 
growth characteristics is very important. As outlined in the introduction, 
differences in human NAT1 expression have been reported to alter cancer cell 
growth properties. The goal of this study was to replicate previous findings and 
investigate further whether differences in human NAT1 expression affect breast 
cancer cell growth and metastatic properties. We knocked-down and 
overexpressed NAT1 using a FRT system (Life Technologies), which facilitates 
investigations of decreased or increased NAT1 expression independent of 
chromosomal position effects because all the expression cassettes were inserted 
into the same genomic location.  
 
NAT1 knockdown using shRNA resulted in approximately 39% reduction 
in NAT1 in vitro catalytic activity, a comparable 35% increase in cellular AcCoA 
levels, and a 7-fold decrease in anchorage-independent growth compared to the 
scrambled shRNA cell line. However the NAT1 shRNA knockdown did not yield 
significant changes (p>0.05) in cell doubling time, anchorage-dependent growth 
or relative invasion ability. Previous studies, using the same NAT1 shRNA 
knockdown plasmid in a colon adenocarcinoma cell line achieved an 80-90% 
knockdown of NAT1 [13] with significant changes in cell growth and invasion but 
only a 15% reduction in anchorage-independent cell growth. The differences 
observed between the present study and the previous NAT1 knockdown study 
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[13] could be due to the different cell line used or the level of NAT1 knockdown. It 
is possible there is a threshold knockdown of NAT1 required to observe effects 
on cell growth and cell invasion that is tissue or cell-type specific.  
 
Despite a 12-fold overexpression of NAT1 in vitro activity, significant 
(p>0.05) changes in endogenous AcCoA levels, cell doubling time, anchorage-
dependent growth, anchorage-independent cell growth, or relative invasion ability 
were not observed. In contrast a previous study using HB4a cells reported that 
NAT1 overexpression resulted in enhanced growth properties [8]. The MDA-MB-
231 cells used in the present study are a claudin-low, triple-negative breast 
cancer cell line whereas the HB4a cell line is derived from normal luminal 
mammary epithelial cells. Thus, the lack of differences between scramble shRNA 
and NAT1 overexpression MDA-MB-231 cell lines may be a result of the cell line 
utilized.  
 
Recent reports that NAT1 catalyzes the hydrolysis of AcCoA in the 
presence of folate suggests that NAT1 may affect endogenous levels of AcCoA 
[54]. Consistent with this concept, we found that partial NAT1 knockdown by 39% 
elevated endogenous AcCoA levels by 35% (figure 4.1C). Although this finding is 
consistent with AcCoA hydrolysis catalyzed by NAT1, it does not provide 
evidence this is the primary or sole mechanism for the elevation of AcCoA. Rat 
embryonic fibroblasts from rapid acetylator congenic rats have lower levels of 
AcCoA than rat embryonic fibroblasts derived from slow acetylator congenic rats 
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[65]. Thus while a direct connection for physiological differences in AcCoA levels 
cannot be drawn to NAT1 AcCoA hydrolysis, accumulating data suggest that 
NAT1 may influence endogenous AcCoA levels. Differences in AcCoA levels 
could provide an explanation for differences in metabolites of fatty acid synthesis 
and amino acids [131]. The effects of NAT1 knockdown on anchorage-
independent cell growth and endogenous AcCoA levels may provide insight into 
why congenic rapid NAT2 (ortholog to human NAT1) activity rats developed more 
mammary tumors than congenic slow NAT2 rats following administration of 
mammary carcinogens that are not metabolized by rat NAT2 [65]. 
 
A second objective of this study was to compare inhibition of NAT1 via a 
small molecule inhibitor to NAT1 knockdown using shRNA. We selected a small 
molecule inhibitor (5-HDST) similar to that identified and characterized previously 
[126]. The scrambled shRNA cell line was utilized as the control in both the small 
molecular inhibitor and shRNA knockdown experiments to facilitate this 
comparison.  
 
5-HDST decreased the ability of the breast cancer cell line to N-acetylate 
PABA in situ. Cell growth was reduced in a concentration dependent manner 
above 50 µM (figure 4.4A). Our experiments did not provide evidence that the 
reduction in cell growth was solely caused by NAT1 inhibition; but did show that 
the concentration-dependent effects on NAT1 catalytic activity and cell growth 
were similar in trend on day six. In the scrambled shRNA cell line incubated with 
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5-HDST, we observed a decrease in both anchorage-dependent and anchorage-
independent cell growth. It is possible that the reduction in anchorage-dependent 
growth reflects cellular toxicity of the small molecule inhibitor. The reduction in 
anchorage-independent growth reflects a combination of cellular toxicity and 
ability of the 5-HDST to inhibit NAT1 and thereby reduce anchorage-independent 
growth in the breast cancer cell line MDA-MB-231.  
 
The IC50 value for the small molecule inhibitor 5-HDST was 47.6 ± 1.07 
µM by in situ PABA N-acetylation inhibition assay. A previous study determined 
an IC50 value of 101 ± 11 µM for (Z)-5-(2-hydroxybenzylidene)-2-
thioxothiazolidin-4-one (Rhod-o-hp), which is structurally similar to 5-HDST, by 
an in situ PABA N-acetylation inhibition assay [11]. The IC50 for 5-HDST also was 
lower than the IC50 for both folate and MTX (76.9 ± 1.05 µM and 127 ± 1.06 µM, 
respectively). Thus, 5-HDST was a more potent NAT1 inhibitor than folate, MTX, 
and Rhod-o-hp. 
 
Previous studies using a different small molecule inhibitor of NAT1 in a 
different cell line reduced cell growth, relative invasion ability and anchorage-
independent cell growth similar to those observed with NAT1 knockdown using 
shRNA [11, 13]. We assessed relative invasion ability using a transwell assay 
and observed no change in the scrambled shRNA cell line treated with the small 
molecule inhibitor 5-HDST until the concentration exceeded 75 µM. 
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Concentrations of 5-HDST as high as 87.5 µM showed no effects on cell viability 
at the 24 hr time point.   
 
In summary, our findings compliment but do not fully replicate previous 
reports regarding the effect of NAT1 knockdown on cancer cell properties. In our 
studies, approximately 40% inhibition of NAT1-catalyzed N-acetylation in the 
MDA-MB-231 breast cancer cell line by either shRNA knockdown or 5-HDST 
resulted in a significant decrease in anchorage-independent growth without 
affecting overall cell growth and relative invasion ability. NAT1 shRNA partial 
knockdown increased endogenous AcCoA levels 35% compared to the 
scrambled shRNA and NAT1 overexpression. The results of our study strongly 
confirm that further studies are needed. Rather than carrying out more extensive 
mechanistic studies on a cell line with a very modest NAT1 knock down (39%), 
we are now utilizing a new model system, CRISPR/Cas9, that makes permanent 
deletions at the NAT1 gene open reading frame causing 100% knockout of 
NAT1. Use of this model, as discussed in the following chapter, has confirmed 
the findings of this study that further suggests that human NAT1 could serve as a 






CRISPR/CAS9 MEDIATED KNOCK OUT OF ARYLAMINE N-
ACETYLTRANSFERASE 1 (NAT1) IN HUMAN ADENOCARCINOMA BREAST 
CANCER CELL LINES 
INTRODUCTION 
 
Modifications of human NAT1 expression within a human cancer cell line 
have mostly either been to overexpress or to knockdown expression partially [8, 
11, 13]. In order to obtain a complete knock out of cellular NAT1 activity CRISPR/ 
Cas9 was utilized to alter the genomic sequence of NAT1 within a cell. There are 
many benefits and some disadvantages in using this rapidly adopted 
experimental technique, however the end result is a novel genomic knockout for 
NAT1. 
 
An initial publication from Ishino et al. in 1987 detailed an observation of a 
cluster of repeat sequences arranged with a spacer sequence, but stated the 
biological significance was unknown [132]. This sequence, with an unknown 
significance, would later be known as Clustered Regularly Interspaced 
Palindromic Repeats (CRISPR). In 2005, the spacer sequences were determined 
to be foreign in origin, and considered to play a role in the organism’s adaptive 
defense system [133-135]. A major requirement was a group of CRISPR-
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associated (Cas) genes/enzymes. The Cas9 gene encodes an RNA guided 
nuclease that targets DNA introduced from phage infections. 
 
Years of work from several groups resulted in understanding the 
mechanism by which the adaptive immunity works, and the functional ability of 
the system within mammalian cells. The mechanism for CRISPR/Cas9 activity 
involves a pair of RNAs that work together to target a specific sequence and a 
large multi-subunit endonuclease complex (Cas9) to cleave the non-host DNA. 
The two RNAs are: “crRNA” that is a processed spacer/repeat sequence and 
“tracrRNA” that shares a complementary region with “crRNA”[136, 137]. When 
these separate RNA sequences bind together they are able to guide Cas9 to a 
specific target site encoded by the spacer sequence. Beside the complementary 
sequence to spacer sequence the DNA sequence must have a protospacer 
adjacent motif (PAM) follow the target site for the cleavage of DNA. The two RNA 
sequences “crRNA” and “tracrRNA” were simplified in 2012 by Jinek et al. when 
they showed that a chimeric transcript, was able to take Cas9 to the target 
sequence and cleave the DNA [138]. 
 
The Cas9/guide RNA (gRNA) complex interacts with complementary 
genomic DNA sequence, and this interaction causes the Cas9 to engage its two-
nuclease domains. The nuclease domains form a double strand break (DSB) 
about 3 nucleotides before the PAM site. The PAM site commonly used is ‘NGG’ 
from Streptococcus pyogenes Cas9 (SpCas9). This PAM site, which occurs 
	
	 88	
frequently in the genome, generally imposes only minimal constraints on target 
site selection and gRNA design.  
 
The cell’s DNA repair pathways repair DNA DSB cleavage resulting from 
Cas9. Those DNA repair pathways are either homologous recombination 
(homology directed-repair (HDR)) or non-homologous end joining (NHEJ). HDR 
repairs a DSB precisely with the aid of a DNA template. While the cell is in cell 
cycle the sister chromatid would serve as the template, however an exogenous 
DNA sequence can allow for a new sequence to be introduced into the genomic 
DNA. The NHEJ is the main DSB repair pathway within most mammalian cells 
with the pathway being active in all phases of the cell cycle. As opposed to HDR, 
NHEJ does not require a homologous DNA sequence to direct the repair of the 
DSB, and this difference often results in genomic insertions/deletions, termed 
indels, after NHEJ repair of DSB. Indels range in size, and if indels occur within 
the protein-coding region of a gene then a frameshift mutation can result. A 
frameshift mutation can produce an amino acid sequence that is terminated 
early. This type of frameshift mutation can effectively produce a knocking out of 
the gene.  
 
To summarize, CRISPR/Cas9 system is composed of three parts. The first 
is the gRNA with a spacer sequence (like from a “crRNA”) to target a DNA 
sequence and a sequence to complex with the Cas9 (like from a “tracrRNA”). 
Cas9 when guided by the gRNA uses the two nuclease-domains to form a DSB 
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just before the PAM site. The PAM site is required for the CRISPR/Cas9 system 
to cleave the targeted DNA sequence. The relative simplicity of the mechanism 
explains the wide and rapid adoption of the technique.  
 
The CRISPR/Cas9 system has some disadvantages that are often under 
represented. The precision of the Cas9 complex (in particular SpCas9) has been 
reported several times to cleave the genomic DNA in unintended sites [139-144]. 
Some gRNAs can act on more than 100 off-target sites [145]. These off target 
breaks have the potential to result in multiple mutations and genomic 
rearrangement, which could alter cellular properties different from that of the 
desired target of the Cas9 complex. 
 
While groups around the world work to improve the precision of individual 
Cas9 complexes, the present study uses two separate gRNAs that target 
separate sequences within the early portion of the NAT1 gene. If an off-target 
event takes place with one gRNA then it will not likely happen in the other gRNA. 
In this scheme for a phenotype to be related to NAT1 knockout both gRNAs must 
display the same phenotype. 
 
This study utilizes two human breast cancer cell lines MDA-MB-231 and 
MCF7. The cell lines originate from separate pleural effusions of different 
malignant breast cancer patients, and have been used for decades in breast 
cancer research. Claudin-low MDA-MB-231 are estrogen receptor negative, 
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progesterone receptor negative, and HER2 negative. MDA-MB-231 cells also 
have little to no cohesion, and are stellate in structure. Luminal A MCF-7 cells are 
estrogen receptor positive, progesterone receptor positive, and HER2 negative. 
MCF7 cell line can form tightly cohesive structures, which show more cell-cell 
adhesions. In using two different cell lines, we are trying to establish if the knock 
out of NAT1 will show similar effects across different breast cancer 
classifications.  
 
To understand better how knocking out NAT1 activity can affect cancer 
cell growth and invasion properties, this study utilized CRISPR/Cas9 technique 
with two unique gRNA sequences for the early portion of the 5’ region of the 
open reading frame for NAT1 gene in human breast cancer cell lines MDA-MB-




MATERIALS AND METHODS 
 
Cell Line Generation and Culturing Conditions 
The cell lines utilized within this study were the MDA-MB-231 and MCF7 
breast adenocarcinoma cell lines obtained from ATCC (Manassas, Virginia). 
Cells were cultured in DMEM media, high glucose with the addition of fetal 
bovine serum to 10% and glutamine to 2 mM. The cell lines were grown in a 
humidified incubator set at 37 °C with 5% CO2. Horizon Discovery Group 
(Cambridge CB525 9TL, United Kingdom) designed the 5 different gRNAs for 
NAT1 and DNA2.0 Inc (Menio Park, CA) cloned the gRNAs into a Cas9 
expressing vector expressing a dasher-GFP tag. Separately, each of the 5 gRNA 
/Cas9 vectors were transiently transfected in MDA-MB-231 cells using the 
Amaxa Nucleofector II (Lonza, Allendale, NJ). Forty-eight hours after transfection 
cells were harvested and DNA isolated. We used the Transgenomic (Omaha, 
NE) SURVEYOR Mutation Detection Kit to determine the effectiveness of each 
gRNA’s ability to cut the genomic and induce DNA strand breaks effectively. The 
gRNAs #2 and #5 were the most effective at inducing DNA strand breaks, and 
where chosen to separately knockout the function of NAT1 in the following 
studies.  
MDA-MB-231 cells were transfected with either #2 or #5 gRNA /Cas9 
vectors as above, and 48 hours after transfection cells were sorted for GFP 
fluorescence. MCF7 was transfected with either #2 or #5 gRNA /Cas9 with 
Lipofectamine 3000 (Invitrogen, California, USA), and 48 hours after 
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transfections cells were sorted for GFP fluorescence. The fluorescent positive 
cells were collected, and plated at a very dilute cell concentration so that 
individual unique clones could be isolated. After several weeks individual cells 
grew into large enough colonies to utilize cloning cylinders to trypsin cells off the 
plate and transfer to a 96-well culture plate. Clones were passaged into a 10 cm 
dish and tested for NAT1 activity. A low number of clones with knockout of NAT1 
activity were selected for further characterization. Knockout clones for NAT1 
activity were screened by sequencing of the NAT1 open reading frame to find 
clones that had deleted/inserted nucleotides that resulted in a frame-shift 
mutation and early protein termination signals resulting in nonfunctional NAT1. 
The individual cloned knockout cell lines representing the knockout of NAT1 
activity for either gRNA #2 or #5 were chosen based upon the measurement of 
NAT1 acetyltransferase activity and genomic sequence.  
 
Sequencing of the NAT1 Gene in the gRNAs #2 and #5 Knockout 
Clones  
Genomic DNA was isolated from both MDA-MB-231 and MCF7 cloned 
knockout cell lines. The NAT1 open reading frame was TOPO cloned using 
pcDNA™ 3.1/V5-His TOPO® TA Expression Kit (Invitrogen, California, USA) 
following manufacture’s recommendations. The TOPO Cloning reaction for the 
individual cell lines was transformed into One Shot TOP10 Chemically 
Competent E. coli. For each NAT1 knockout cell line, five transformed E. coli 
colonies were selected and grown overnight. Cultures of bacteria were then 
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harvested for plasmid purification. Purified plasmids and primers were sent for 
DNA sequencing (Eurofins, Louisville, KY, USA). Sequence data was analyzed 
and aligned with SeqMan Pro™ (Version 12.0, DNASTAR, Madison, WI.) 
 
In Vitro and In Situ NAT1 N-acetyltransferase Assays  
In vitro assays using the NAT1 selective substrate para-aminobenzoic 
acid (PABA) were conducted and acetylated products were separated and 
quantitated as described [129]. Briefly, cells were scraped from the plate, washed 
in 1X phosphate-buffered saline (PBS), and lysed in 20 mM sodium phosphate 
pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.2% triton X-100,, 1 mM 
dithiothreitol (DTT), 100 µM phenylmethanesulfonyl fluoride (PMSF), 1 µg/ml 
aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10 
min and supernatant tested for NAT1 activity. Enzymatic reactions containing 50 
µL suitably diluted cell lysate, PABA (300 µM) and acetyl coenzyme A (1 mM) 
were incubated at 37°C for 10 min. Reactions were terminated by the addition of 
1/10 total reaction volume of 1 M acetic acid and centrifuged at 15,000 X g for 10 
min. Three independent measurements (N=3) performed in triplicate were 
completed for each cell line. 
 
Measurement of N-acetylation in situ was determined by spiking media 
with a known concentration of PABA as described [130]. The cells were 
incubated at 37°C for 48 h with media containing 500 µM PABA. Media were 
collected, and 1/10 total collected media volume of 1 M acetic acid was added. 
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Then the acidified media were centrifuged at 15,000 X g for 10 min. There were 
three independent measurements (N=3) for MDA-MB-231 and four independent 
measurements (N=4) for MCF7 all performed in triplicate.  
 
Resulting supernatants from in vitro and in situ NAT1 activity assays were 
injected into a reverse phase C18 column (125 mm × 4 mm; 5 µM pore size). 
Reactants and products were eluted using a Beckman System Gold high 
performance liquid chromatography (HPLC) system. HPLC separation of N-
acetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 2.5: 
acetonitrile at 280 nm. The data for scrambled shRNA, knockdown and 
overexpression cell lines are represented as mean ± SEM and analyzed 
statistically by a one-way ANOVA and Bonferroni post hoc test. 
 
Endogenous Acetyl-Coenzyme A (AcCoA) Levels  
Endogenous AcCoA levels within modified MDA-MB-231 and MCF7 
cancer cell lines were determined by HPLC-UV. Cell growth conditions were 
strictly monitored because it was observed that cellular confluence and period of 
growth affected the consistency of data obtained for the endogenous AcCoA 
concentrations. Cells were plated at 1 x 106 per 10 cm plate (3 plates per N) with 
fresh complete culturing media with no selection antibiotic added, and allowed to 
grow for 72 h. After 72 h, the cells were 70% confluent and collected. Media were 
aspirated from the plates, and each plate was washed with 5 ml PBS. Then cells 
were dissociated from the plate with 0.5 ml trypsin [0.25% (w/v)]. Cells were 
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suspended in 4 ml of diluted complete media (20% medium and 80% PBS) and 
counted in 0.5 ml aliquots. In the subsequent steps all cells and lysates were 
kept on ice or at 4°C. Collected cells were centrifuged, supernatant removed, and 
ice-cold PBS was added. Again, cells were centrifuged, supernatant removed, 
suspended in 1 ml of ice-cold PBS, and transferred to 1.5 ml microcentrifuge 
tubes. The suspended cells were collected by centrifugation and the 
supernatants discarded. Having removed any residual PBS, the cells were lysed 
in 100 µL ice-cold 5% 5-sulfosalicylic acid with a 1 ml BD Insulin Syringe with 
permanently attached 28 gauge needle (BD Franklin Lakes, NJ, USA). The 
needle selection is important to insure complete cell lysis without loss of volume 
or cellular masses within the syringe/needle. The cellular lysate was then 
centrifuged at 13,000 x g for 10 min. Supernatant was filtered through a syringe 
filter (13 mm, 0.20 µm pore size). Filtrate was collected and separated on a C18 
reverse-phase HPLC column (250 mm × 4 mm; 5 µm pore size). HPLC 
separation and quantitation of AcCoA was achieved using a linear gradient of 
100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium 
phosphate pH 4.0: 100% methanol over 20 min and was quantitated by 
absorbance at 260 nm. The data for individual determinations of CRISPR clones 
are represented as mean ± SEM with eight independent measurements (N=8) for 
MDA-MB-231 and twelve independent measurements (N=12) for MCF7. Data 





Determination of Doubling Time  
Twenty-five thousand cells were plated in triplicate in 6-well plates and 
allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed 
to equilibrate for 24 h before making the first count on day 2 followed by counts 
on days 3, 4, 5 and 6 using a cell counter. A cell doubling rate was calculated for 
each day using Equation 1 (shown below) and then rates were averaged over the 
5 day time period to get a final cell doubling rate.  
 
Equation 1: Cell Doubling Rate = 1/(((log b − log (a))×3.32)/(t! − t!)) 
 
In the equation, b = cell number on day n, a = cell number on day n-1, t! = 
hours passed since plating when cells were counted on day n, and t! = hours 
passed since plating when cells were counted on day n-1. This assay was 
performed in triplicate for each cell line (N=3). The data for the cell lines are 
represented as mean ± SEM from three separate determinations performed in 
triplicate, and were analyzed statistically by a one-way ANOVA and Bonferroni 
post hoc test. 
 
Anchorage-Dependent and Anchorage-Independent Growth Assay 
Anchorage-dependent growth assays were performed by plating cells (300 
cells/well) in triplicate in 6-well plates and allowing them to grow for 2 weeks. 
Colonies were counted following staining with crystal violet. The data are 
represented as means ± SEM from six independent measurements (N=6) for 
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MDA-MB-231 and seven independent measurements (N=7) for MCF7 all 
performed in triplicate, and were analyzed statistically by a one-way ANOVA and 
Bonferroni post test. 
 
The anchorage-independent growth assays were performed by plating the 
cells in low-melting temperature agarose. The cells were grown in normal growth 
media where the bottom layer was 1.5 ml (noble agar, 0.5%) and the top layer 
was 1.5ml (low-melting temperature agarose, 0.3%), so the total volume was 3 
ml in each well of a 6 well plate. Cells (6000 cells/well) were plated in triplicate in 
6-well plates and grown for 2 weeks. Colonies were counted following staining 
with crystal violet. Three independent measurements (N=3) for MDA-MB-231 and 
four independent measurements (N=4) for MCF7 performed in triplicate were 
completed for each assay. The data are represented as means ± SEM and were 
analyzed statistically by a one-way ANOVA and Bonferroni post hoc test. 
 
Anoikis Assay and Hanging Drop Assay 
The anoikis assay required the wells of 96-well plates to be coated with a 
polymer known as poly-HEMA (Sigma). The poly-HEMA powder was dissolved in 
95% ethanol at a concentration of 50 mg/ml to generate a stock solution. The 
working solution for poly-HEMA was made by diluting the 50 mg/ml stock at a 
1:10 ratio in 100% ethanol to a final concentration of 5.0 mg/ml. The wells of 96-
well plates were coated with two layers of poly-HEMA, and the plates were dried 
overnight between each coating. Each experimental well, with or without poly-
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HEMA coating, was given 4.0 x 103 MDA-MB-231 cells in 100 µL of complete 
media. Controls wells with or without poly-HEMA coating had no cells included. 
Cells were incubated overnight before recording the 0 hour reading. Number of 
cells within each well was quantified by AlmarBlue® cell quantitation assay. 
Briefly, each well received 10 µL of AlmarBlue® and incubated for an additional 3 
hours, and then fluorescence read on a plate reader for 0 to 96 hours measured 
at 24 hour time points. Three separate determinations performed in triplicate 
were made (N=3). The data are represented as means ± SEM, and were 
analyzed statistically by two-way ANOVA and Bonferroni post hoc test. 
 
Hanging drop assay was performed by suspending 12.5 µl complete 
culture media droplets containing 5000 MDA-MB-231 cells onto the inner surface 
of the lid of a 10 cm culture dish. Ten ml of PBS was placed into the dish to 
prevent evaporation of the hanging droplets. Cells within four individual droplets 
were counted by trypan blue exclusion for the number of dead cells compared to 
the number of live cells per individual determination (N). The time points were 24, 
48 and 72 hours. Seven separate determinations performed in quadruplicate 
were made (N=7). The data are represented as means ± SEM, and were 
analyzed statistically by two-way ANOVA and Bonferroni post hoc test. 
 
Transwell Assays to Assess Relative Invasive Ability  
The inserts of permeable Transwell wells were either coated with or 
without 100 µl of 0.5 mg/ml Matrigel (Life Technologies), and the Matrigel was 
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allowed to solidify for 2 h at 37°C. Upper chambers of the transwells were 
seeded with either 2.5 X 104 or 5 X 104 MDA-MB-231 cells in 100 µl of media 
containing 0% FBS. The bottom chamber of the transwells contained 600 µL of 
complete media. Cells were incubated at 37°C with 5% CO2 and allowed to 
invade across the Matrigel for 24 h. After incubation, cells on the topside of the 
transwell membrane were removed with a sterile cotton swab. Cells that invaded 
across the membrane were counted utilizing crystal violet staining. Four separate 
determinations performed in duplicate were made (N=4). The data are 
represented as means ± SEM, and were analyzed statistically by one-way 
ANOVA and Bonferroni post hoc test. 
 
In Vitro Wound-Closure Assay 
The method is based on the previous protocol published by Peterson et al. 
in 2014 [146]. Silicone elastomer base (Sylgard 184 Elastomer; Dow Corning, 
Midland, MI, USA) was prepared per manufacturer's directions. A 2-mm biopsy 
punch was used to create five silicone plugs/well. The plugs were placed directly 
on the bottom of a 6-well plate. MDA-MB-231 and gRNA #2 and #5 clones were 
plated at a concentration of 600,000 cells/well and incubated for 48 hours so that 
the cells are confluent around the plugs. Plugs were removed to create a 2-mm 
diameter area and the remaining cells were washed twice with PBS. The cell free 
area created by the plug was photographed each day. The area free of cells was 
quantified for each time point using ImageJ software (http://imagej.nih.gov/ij/; 
provided in the public domain by the National Institutes of Health (Bethesda, MD, 
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USA) [147]. Data were plotted as the percentage of the initial area that was 
covered (wound closure) for each time point. Each data point represents means 
± SEM for three separate determinations performed in triplicate (N=3).  
 
Subcutaneous Xenograft of MDA-MB-231 Cells 
NOD-Rag1null Il2rgnull (NRG) mice, provided by Dr. Levi Beverly’s 
laboratory, were housed in the University of Louisville animal facility and the 
experiment was reviewed and approved by the University’s Institutional Animal 
Care and Use Committee. The parental (N=10) and knockout (N=5 for each 
knockout cell line) MDA-MB-231 cell lines (1 X 106) were injected 
subcutaneously into the right or left flank, respectively, of 18 week old female 
NRG mice. Tumors where collected after six weeks, and weighed before being 
flash frozen. The data are represented as means ± SEM, and were analyzed 






NAT1 Genomic and Amino Acid Sequence  
Sequencing for MDA-MB-231 cell lines characterized gRNA #2 (clone 2-
19) knockout cell line with a deletion in the open reading frame, which is the 
deletion of a cytosine nucleotide at base 96 of 870 bp (table 5.1). This single 
nucleotide deletion resulted in a frameshift causing a premature stop codon after 
amino acid 49 of 290 (table 5.2). The gRNA #5 (clone 5-50) knockout cell line 
had two nucleotides deleted at 43 and 44 bp downstream of the start codon 
(table 5.1). This deletion resulted in a premature stop codon after amino acid 
codon 14 of 290, which immediately terminates translation of NAT1 (table 5.2). 
 
Sequencing results for MCF7 show that gRNA #2 (clone 2-4) knockout cell 
line has a 34 bp deletion in the open reading frame, which spans from 95 to 129 
bp (table 5.3). This deleted segment of DNA resulted in a frameshift causing a 
premature stop codon after 38 amino acids (table 5.4). The gRNA #5 (clone 5-
20) knockout cell line had two separate deletions. The first deletion was a single 
nucleotide deletion at bp 42, and the other was a deletion of bp 43 to bp 48 with 
an adenine insertion in the same region (table 5.3). These indel deletions 
resulted in a premature stop codon after amino acid codon 23 for both 




Table 5.1 – Genomic sequence for the NAT1 gene in MDA-MB-231 Parental and NAT1 knockout clones 
 
 
Cell line bp # Genomic Sequence bp# 
Parental 76 GACATTCTTCAACACCAGATCCGAGCTGTT 105 
gRNA #2 clone 76 GACATTCTTCAACACCAGATC-GAGCTGTT 105 
Parental 21 TGAAAGAATTGGCTATAAGAAGTCTAGGAA  50 





Table 5.2 – Resulting Amino Acid Sequence for MDA-MB-231 Parental and NAT1 knockout clones 
 
 
Cell line Amino Acid Sequence # of AA 
Parental M D I E A Y L E R I G Y K K S R N K L D L E T L T D I L 
Q H Q I R A V P F E N L N I H C G D A M D L G L E A I F 
D Q V V R R N R G G W C L Q V N H L L Y W A L T T I G F 
E T T M L G G Y V Y S T P A K K Y S T G M I H L L L Q V 
T I D G R N Y I V D A G F G R S Y Q M W Q P L E L I S G 
K D Q P Q V P C I F R L T E E N G F W Y L D Q I R R E Q 
Y I P N E E F L H S D L L E D S K Y R K I Y S F T L K P 
R T I E D F E S M N T Y L Q T S P A S V F T S K S F C S 
L Q T P D G V H C L V G F T L T H R R F N Y K D N T D L 
I E F K T L S E E E I E K V L K N I F N I S L Q R K L V 




M D I E A Y L E R I G Y K K S R N K L D L E T L T D I L 









Table 5.3 – Genomic sequence for the NAT1 gene in MCF7 Parental and NAT1 knockout clones 
 
 
Cell line bp # Genomic Sequence bp# 
Parental 91 CAGATCCGAGCTGTTCCCTTTGAGAACCTTAACATCCATTGTGGG 135 
gRNA #2 
clone 91 CAGAT----------------------------------TGTGGG 135 
Parental 31 GGCTATAAGAAGTCTAGGAACAAATTGGAC 60 
gRNA #5 
clone  31 GGCTATAAGAA-TCTAGGAACAAATTGGAC 60 
gRNA #5 




Table 5.4 – Resulting Amino Acid Sequence for MCF7 Parental and NAT1 knockout clones 
 
 
Cell line Amino Acid Sequence # of AA 
Parental M D I E A Y L E R I G Y K K S R N K L D L E T L T D I L 
Q H Q I R A V P F E N L N I H C G D A M D L G L E A I F 
D Q V V R R N R G G W C L Q V N H L L Y W A L T T I G F 
E T T M L G G Y V Y S T P A K K Y S T G M I H L L L Q V 
T I D G R N Y I V D A G F G R S Y Q M W Q P L E L I S G 
K D Q P Q V P C I F R L T E E N G F W Y L D Q I R R E Q 
Y I P N E E F L H S D L L E D S K Y R K I Y S F T L K P 
R T I E D F E S M N T Y L Q T S P A S V F T S K S F C S 
L Q T P D G V H C L V G F T L T H R R F N Y K D N T D L 
I E F K T L S E E E I E K V L K N I F N I S L Q R K L V 




M D I E A Y L E R I G Y K K S R N K L D L E T L T D I L 




M D I E A Y L E R I G Y K N L G T N W T W K H Stop 23 
gRNA #5 
clone 





In Vitro and In Situ PABA Acetylation Activity 
The in vitro N-acetylation of PABA in MDA-MB-231 parental cell was 14.4 
± 1.63 nmoles/min/mg of protein (figure 5.1A). The CRISPR gRNA #2 and #5 
clones reduced levels of activity to below a detectable level, with the limit of 
detection 0.05 nmoles/min/mg of protein (figure 5.1A). The N-acetylation of 
PABA in situ per hour per million cells followed the same pattern as the in vitro 
activity. N-acetylation of PABA in the parental MDA-MB-231 cell line activity was 
1.15 ± 0.022 nmoles/hr/million cells (figure 5.1C). In the gRNA #2 and #5 clones, 
levels of PABA N-acetylation in situ were reduced to below a detectable level, 
with the limit of detection 0.20 nmoles/hr/million cells (figure 5.1C). 
 
The in vitro acetylation of PABA activity for MCF7 parental cell lysates was 
39.0 ± 3.42 nmoles/min/mg of protein (figure 5.1B). The CRISPR gRNA #2 and 
#5 clones had levels of activity reduced to below a detectable level, with the limit 
of detection 0.05 nmoles/min/mg of protein (figure 5.1B). The N-acetylation of 
PABA in situ per hour per million cells followed the same pattern as the in vitro 
activity. N-acetylation of PABA in the parental MCF7 cell line was 2.20 ± 0.357 
nmoles/hr/million cells (figure 5.1D). In the gRNA #2 and #5 clones, levels of 
PABA N-acetylation in situ were reduced to below a detectable level, with the 
limit of detection 0.20 nmoles/hr/million cells (figure 5.1D).
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Endogenous AcCoA Levels  
The endogenous level of AcCoA within the MDA-MB-231 parental cell line 
was 17.8 ± 1.1 pmoles/million cells (figure 5.1E). The endogenous level of 
AcCoA within the cells of the gRNA #2 and #5 NAT1 knockout clones was 33.1 ± 
1.8 and 35.5 ± 2.6 pmoles/million cells, respectively (figure 5.1E). Overall 
endogenous levels of AcCoA within the gRNA #2 and #5 NAT1 knockout clones 
were significantly elevated compared to their MDA-MB-231 parental cell line 
(N=8; p<0.05) (figure 5.1E). 
 
MCF7 parental cell line had an endogenous level of AcCoA of 18.7 ± 
0.897 pmoles/million cells (figure 5.1F). The endogenous levels of AcCoA within 
the cells of the gRNA #2 and #5 NAT1 knockout clones were 27.6 ± 2.60 and 
27.0 ± 2.72 pmoles/million cells, respectively (figure 5.1F). Overall endogenous 
levels of AcCoA within the gRNA #2 and #5 NAT1 knockout clones were 









Figure 5.1 - NAT1 PABA acetylation activity and endogenous AcCoA 
concentration level in genomic modified MDA-MB-231 and MCF7 cell lines. Each 
bar illustrates mean ± SEM. The in vitro PABA N-acetylation (A-B) activity in cell 
line lysates (N=3). The in situ PABA N-acetylation (C-D) in MDA-MB-231 (N=3) 
and MCF7 (N=4) cell lines cultured in PABA spiked media. The endogenous 
AcCoA levels (E-F) for MDA-MB-231 (N=8) and MCF7 (N=12) cell lines. 
Differences between cell lines were significantly different (* p≤ 0.05; *** p≤ 0.001) 
























































































































































































































Cell Line Doubling Times 
The doubling times for the parental cell line and gRNA #2 and #5 NAT1 
knockout cell lines were 30.5 ± 1.0, 29.3 ± 1.1, and 29.8 ± 0.7 hours, respectively 
(N=3)(figure 5.2A). Neither of the gRNA NAT1 knockout clone cell lines 
significantly altered the doubling time compared to the parental MDA-MB-231 cell 
line. Differences were tested for statistical significance by one-way ANOVA (p> 
0.05). 
 
MCF7 parental cell line and gRNA #2 and #5 NAT1 knockout cell lines 
exhibited doubling times of 41.4 ± 0.4, 45.3 ± 6.2, and 38.8 ± 8.5 hours, 
respectively (N=3)(figure 5.2B). Neither of the gRNA NAT1 knockout clone cell 
lines significantly affected the doubling time compared to the parental MCF7 cell 
line. Differences were tested for statistical significance by one-way ANOVA (p> 
0.05). 
 
Anchorage-Dependent and -Independent Colony Formation Assay 
The ability of colony formation by anchorage-dependent manner was 
quantified for MDA-MB-231 parental (40.7 ± 2.54 colonies) and gRNA #2 (51.3 ± 
1.61 colonies) and #5 (54.8 ± 6.76 colonies) NAT1 knockout modified cell lines. 
Anchorage-dependent colonies among the MDA-MB-231 and NAT1 knockout 
cell lines did not differ statistically from each other tested by a one-way ANOVA 




MCF7 parental and gRNA #2 and #5 NAT1 knockout modified cell lines 
ability of colony formation by anchorage-dependent manner was quantified as 
50.7 ± 5.2, 80.6 ± 6.4, and 41.5 ± 6.2 colonies, respectively. MCF7 gRNA #2 
clone cell line formed statistically more colonies than the parental and gRNA #5 
clone cell lines when tested by a one-way ANOVA followed by Bonferroni post 
hoc test (p<0.0005; N=7) (figure 5.2D).  
 
Anchorage-independent colony formation assays (also known as “soft 
agar assays”) allow for the determination of cancer cell ability to form colonies in 
the absence of cellular attachment to a surface. The MDA-MB-231 parental cell 
line formed anchorage-independent colonies at markedly higher levels than the 
NAT1 knockout clones (figure 5.2E). The number of colonies formed by MDA-
MB-231 parental and gRNA #2 and #5 NAT1 knockout modified cell lines were 
1070 ± 76, 48.3 ± 17.2, and 23.4 ± 7.0 colonies, respectively. The anchorage-
independent colony formation of MDA-MB-231 parental cell line was significantly 
higher than their CRISPR NAT1 knockout peers when tested by one-way 
ANOVA followed by Bonferroni post hoc test (p<0.0001; N=3). The same 
Bonferroni post test showed that the two CRISPR NAT1 knockout cell lines were 
not statistically (p>0.05) different from each other.  
 
MCF7 parental cell line formed anchorage-independent colonies at a 
higher level than the NAT1 knockout MCF7 cell line clones (figure 5.2F). The 
number of colonies formed by MCF7 parental and gRNA #2 and #5 NAT1 
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knockout cell lines were 195 ± 9, 33.7 ± 6.8, and 13.8 ± 6.6, respectively. 
Anchorage-independent colonies formed by the MCF7 parental cell line were 
significantly higher than gRNA #2 and #5 NAT1 knockout clones by one-way 
ANOVA followed by Bonferroni post hoc test (p<0.0001; N=4). The MCF7 gRNA 
#2 and #5 NAT1 knockout clones were not statistically different (p>0.05) from 






Figure 5.2 - Cell growth properties in genomic modified MDA-MB-231 and MCF7 
cell lines. Each bar illustrates mean ± SEM. Cell doubling times (A-B) in MDA-
MB-231 and MCF7 NAT1 knockout cell lines did not differ significantly from 
parental cell lines following one-way ANOVA (p>0.05) (N=3). The anchorage-
dependent growth (C) did not differ significantly among the MDA-MB-231 cell 
lines following one-way ANOVA (p>0.05) (N=6). MCF7 CRISPR gRNA #2 clone 
cell line formed more anchorage-dependent colonies than the parental and 
CRISPR gRNA #5 clone cell lines (D) according to an one-way ANOVA followed 
by a Bonferroni post-test (** p≤ 0.001 and *** p≤ 0.001) (N=7). The NAT1 
knockout cell lines formed significantly less anchorage-independent colonies 
compared to parental cell lines (E-F) for both MDA-MB-231 (N=3) and MCF7 
(N=4) determined by one-way ANOVA followed by a Bonferroni post-test (*** p≤ 
0.001). No significant differences in anchorage-independent colonies between 









































































































































Anoikis Assay and Hanging Drop Assay 
Cancer cells were measured for anoikis resistance by being cultured 
under anchorage independent conditions. Anchorage independent growth 
conditions were achieved by coating wells of a 96-well plate with poly-HEMA, 
which keeps cells from attaching to the bottom of the well. In anchorage 
independent growth conditions the growth curves of MDA-MB-231 parental and 
gRNA #2 and #5 knockout cell lines do not significantly differ from their 
respective cells grown in anchorage dependent conditions (N=3)(figure 5.3 A-C). 
When parental and NAT1 knockout clones are compared between each growth 
condition there was no significant difference observed (figure 5.3D and E). 
 
To address the growth of MDA-MB-231 parental and knockout cell lines in 
anchorage independent growth conditions and in close cellular proximity a 
hanging drop assay was conducted. The results suggest that over the course of 
time knockout of NAT1 within MDA-MB-231 cancer cells results in aggregating 
and forming a mass of cells sooner that the parental cell line (figure 5.4A). If the 
ratio of dead cells to live cells is measured by trypan blue exclusion, the gRNA 
#2 and #5 NAT1 knockout clone cell lines developed a higher ratio of dead cells 
to live cells compared to the parental MDA-MB-231 cell line according to a two-
way ANOVA (figure 5.4B) (interaction p<0.0001, N=7). At the 72 hour time point 
both the gRNA #2 and #5 NAT1 knockout clone cell lines had significantly higher 





The relative invasion ability of MDA-MB-231 parental and gRNA #2 and #5 
NAT1 knockout clones were found not to differ significantly when compared by a 
by one-way ANOVA and Bonferroni post hoc test (p>0.05; N=4)(figure 5.5B). 
 
Wound Closure for MDA-MB-231 Cell Lines 
MDA-MB-231 gRNA #2 and #5 NAT1 knockout clone cell lines closed 
more of a wound than the MDA-MB-231 parental cell line parental cell lines 
(figure 5.6A). The linear slopes for the NAT1 knockout cell lines were found to be 
significantly higher than the linear slope of the parental cell line (p<0.01; N=3) 
(figure 5.6B).    
 
Subcutaneous Xenograft of MDA-MB-231 Cell Lines 
The removed xenograft tumors of MDA-MB-231 cells weighed 0.448 ± 
0.0696 grams for parental cell line, 0.308 ± 0.0515 grams for gRNA #2 NAT1 
knockout clone, and 0.463 ± 0.128 grams for gRNA #5 NAT1 knockout clone. 
There was no difference in the total tumor weights of the isolated tumors 







Figure 5.3 - Growth curves for MDA-MB-231 cell lines with standard adhesion or 
in anchorage-independent conditions. Parental and CRISPR gRNA knockout 
clone cell lines growth curves comparing their ability to grow in standard non-
coated wells versus poly-HEMA coated wells (anchorage independent 
conditions) (A-C). Parental and the CRISPR/Cas9-mediated NAT1 knockouts 
display a level of anoikis resistance when compared to standard anchorage 
growth. Comparisons of the two different conditions for each cell line found no 
statistical difference (A, p=0.63; N=3 / B. p=0.88; N=3 / C, p=0.72; N=3). The 
NAT1 knockout cell lines have comparable growth and anoikis resistance to the 
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Figure 5.4 – Comparison of representative photomicrographs taken of the 
hanging drops showing the cells four days (A). The CRISPR knockout MDA-MB-
231 clone cell lines (#2 and #5) each form tightly packed, often singular, cellular 
masses. However the parental MDA-MB-231 cells remain relatively diffused by 
the fourth day. The cells are collected and counted using trypan blue exclusion to 
determine the ratio of “dead cells” to “live cells” within a drop (B). The parental 
MDA-MB-231 cells seem to remain at the same ratio of dead to live cells over the 
course of three days. However NAT1 knockout clones increase in the ratio of 
dead cells to live cells over the course of days. This is found to be significantly 
different by two-way ANOVA (interaction p<0.0001; N=7) followed by a 
Bonferroni post hoc test (** p≤ 0.01; *** p≤ 0.001 for the 72 hour time point).  
 
























































Figure 5.5 –Comparison of photomicrographs taken of Transwell® membranes 
illustrating the different number of cells that were able to reach the bottom side of 
the membrane either with or without Matrigel for parental or NAT1 knockout cell 
lines (A). The gel concentration is given along the top of the columns as mg/ml, 
and then directly below is the number of cells that were seeded into the 
Transwell® insert. Relative Invasion ability for either MDA-MB-231 parental or 
NAT1 knockout cell lines (B). Relative invasiveness was calculated by dividing 
the cells that invaded thru the 0.5 mg/ml gel matrix (insert seeded with 50,000 
cells) by the number of cells that migrated through no gel (insert seeded with 
25,000 cells). The relative invasiveness ability for each cell line was non-


































































Figure 5.6 – Percentage of closure for a 2 mm diameter wound over the course 
96 hours. The CRISPR gRNA #2 and #5 NAT1 knockout clone cell lines have a 
higher percentage of closure that the MDA-MB-231 parental cell line over the 96 
hours (A). The rate of closure is elevated in the NAT1 knockout cell lines 
compared to the rate for the parental MDA-MB-231 cell line (B). This elevated 
rate for NAT1 knock out cells was found to be significant by a one-way ANOVA 
































































Figure 5.7 – The removed xenograft tumor weights for MDA-MB-231 parental 
(N=10), gRNA #2 clone (N=5) and gRNA #5 clone (N=5) were not significantly 

























CRISPR/Cas9 was used to produce cloned cell lines with a stable 
knockout of NAT1 in human MDA-MB-231 and MCF7 breast cancer cell lines. 
This study served to replicate previous findings with partial shRNA knockdowns, 
and confirmed differences in human NAT1 expression effects within breast 
cancer cell lines. Differences in human NAT1 expression have been reported to 
alter cancer cell growth properties, and understanding how NAT1 gene 
expression affects cancer cell growth characteristics is very important. 
 
MDA-MB-231 and MCF7 gRNA #2 and #5 NAT1 knockout clones resulted 
in no measurable PABA acetylation either in vitro or in situ assays, at least a 
45% increase of endogenous AcCoA levels, and at least a 6-fold decrease in 
anchorage-independent growth compared to the parental MDA-MB-231 and 
MCF7 cell lines. However knockout of NAT1 produced no significant changes 
(p>0.05) in cell doubling time, anchorage-dependent growth, or relative invasion 
ability compared to parental MDA-MB-231 cells. MCF7 parental and knockout 
clone cell lines showed no significant difference (p>0.05) in doubling time. The 
MCF7 gRNA #2 clone formed more anchorage-dependent colonies that the 
MCF7 parental and gRNA #5 clone cell lines. This elevation of colonies in MCF7 
gRNA #2 clone is not related to the knockout of NAT1 since it is not found in the 
MCF7 gRNA #5 clone, and the results from other model systems show no 
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increase in anchorage-dependent colonies. So this increase can be the result of 
an off target effect. 
 
The combined results with NAT1 knockout cell lines show no difference in 
doubling time compared to the parental cell lines. The number of anchorage-
dependent colonies was found to be independent of the NAT1 activity level in 
these breast cancer cell lines. The relative cellular invasion ability was found to 
be non-significantly different between MDA-MB-231 parental cells and NAT1 
knockout cells. These findings suggest that NAT1 does not play a role in growth 
rates, anchorage-dependent colony formation, or relative invasion ability for 
breast cancer cells under cell culture conditions. This conclusion is different from 
that of previous reports [11, 12]. 
 
NAT1 hydrolysis of AcCoA in the presence of folate compounds suggests 
that NAT1 may affect endogenous levels of AcCoA [54, 103]. Consistent with this 
concept, NAT1 knockout elevated AcCoA levels in both the MDA-MB-231 and 
MCF7 cell line model systems. Rat embryonic fibroblasts from rapid acetylator 
congenic rats have lower levels of AcCoA than rat embryonic fibroblasts derived 
from slow acetylator congenic rats [65]. Partial knockdown of NAT1 in MDA-MB-
231 also showed elevated levels of AcCoA compared to the wildtype (scramble 
shRNA) MDA-MB-231 cell line. A direct connection for physiological differences 
in AcCoA levels drawn to NAT1 AcCoA hydrolysis requires further investigation. 
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However the current accumulating data show that NAT1 influences endogenous 
AcCoA levels. 
 
Anchorage-independent growth decreased 12-fold in MDA-MB-231 and 6-
fold in MCF7 cells when NAT1 activity was knocked out. Based on this result, it is 
hypothesized that the removal of NAT1 activity reestablished anoikis ability within 
the cell lines. Anoikis is an anchorage-related apoptosis that results from the loss 
of integrin-mediated cell-matrix contact. In the absence of attachment to 
extracellular matrix (ECM) or upon cell adhesion to inappropriate location, cells 
undergo this type of apoptosis. Integrin receptors mediate the cell to ECM 
interactions providing physical links with the cytoskeleton and transduce signals 
from the ECM to the cell. The transduction of signals is mandatory for several 
cellular processes including migration, proliferation and survival [148-151]. 
Anoikis serves as a defense mechanism within an organism. The defense 
mechanism prevents detached cells reattaching to incorrect ECM locations and 
proliferating. Cells that lack or have a reduced anoikis response can result in 
cells surviving under suspension conditions and/or proliferating at ectopic sites 
with a different ECM. Decreased regulation of anoikis is emerging as a hallmark 
of cancer cells and contributes to the formation of metastasis in distant organs 
[148-151]. 
 
However testing for reestablishment of anoikis revealed that anchorage 
independent growth rates, determined from growth in poly-HEMA coated plates, 
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were not different between MDA-MB-231 parental and NAT1 knockout clone cell 
lines. This finding means that anoikis is unlikely the cause of the dramatic 
differences in anchorage-independent colony formation. A hanging drop assay 
revealed an elevated ratio of dead to live NAT1 knockout cells compared to the 
parental cell line. In the hanging drop assay, the cells grow in anchorage-
independent conditions, but are forced to gradually come into contact with each 
other. This result is suggestive that the NAT1 knockout cell lines are more 
sensitive to the cell-cell contacts than the parental cell line. So instead of anoikis 
reestablishment, the close proximity of other cells may be the cause for a lower 
number of anchorage-independent colonies. The wound closure assay with 
MDA-MB-231 cells showed that NAT1 knockout cell lines enter an open growth 
area at higher rates compared to the parental cell line, which was observed in the 
closure rates for each cell line.  
 
Subcutaneous xenograft of MDA-MB-231 NAT1 knockout cells developed 
into a tumor with the same masses as the parental cells. This result is consistent 
with cell culture results showing no difference in anchorage-dependent growth. A 
future experiment with tail vein injections of cancer cells and measuring lung 
metastasis may result in the NAT1 knockout cells producing lower tumor rates 
than parental cells. This theory is based on published data using similar methods 
[12]. Also this methodology of tail vein injection requires cancer cells to flow 
through the blood stream and grow from individual cells into a lung metastasis, 
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which is a better representation of the cell culture anchorage-independent 
findings.  
 
In summary, our findings compliment but do not fully replicate previous 
reports regarding the effect of reducing NAT1 activity on cancer cell properties. In 
our studies, complete removal of NAT1-catalyzed N-acetylation in the MDA-MB-
231 and MCF7 breast cancer cell line by CRISPR/Cas9 resulted in a significant 
decrease in anchorage-independent colony formation without affecting overall 
cell growth and relative invasion ability. NAT1 knockout cell lines had increased 
endogenous AcCoA levels, about 45%, compared to the parental cell line. The 
results warrant further studies to determine mechanisms to understand how 
reduced NAT1 activity is related to reduced formation of anchorage-independent 
colonies. Use of this model system further suggests that human NAT1 could 






SUMMARY AND CONCLUSIONS 
The results presented within this dissertation show the possible role of 
NAT1 in tumorigenesis and cell biology. To come upon these results experiments 
were conducted using in vitro enzymatic reactions, in vivo studies with 
homozygous high (rapid) or low (slow) NAT2 activity congenic rats, and 
genetically modified cancer cell lines. The second chapter shows that human 
NAT1 and rodent NAT2 hydrolyze AcCoA in a folate dependent manner. The 
third chapter shows that rapid NAT2 congenic rats develop more tumors than the 
slow NAT2 congenic strain following administration of MNU and DMBA 
carcinogens, which are both not metabolized by rat NAT2. The fourth and fifth 
chapters are studies performed with partial NAT1 knockdown and complete 
NAT1 knockout human breast cancer cell lines, respectively. The findings conflict 
with some previous findings on knockdown cell lines, but also share a common 
result. In both the partial knockdown and complete knockout cell lines 
anchorage-independent colony formation ability in soft agar is greatly diminished 
compared to parental cell lines. Endogenous AcCoA levels in congenic slow 
NAT2 rat embryonic fibroblasts, partial NAT1 knockdown cell line, and complete 
NAT1 knockout cell lines show increased AcCoA when NAT activity is reduced 
within the cell. The “complete mechanism/role” of NAT1 is still debatable, 
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however this dissertation provides evidence that NAT1 influences mammary 
cancer susceptibility and has an endogenous role within a cell. 
 
The second chapter, first results section, shows human NAT1 and the 
rodent ortholog NAT2 can perform AcCoA hydrolysis in the presence of folate but 
absence of xenobiotic substrate (e.g. PABA). The human NAT2 and the rodent 
Nat1 have no detectable AcCoA hydrolysis activity. A HPLC method was 
developed to measure the level of CoA and AcCoA. We determined the 
Michaelis-Menton kinetic constants (Vmax and Km) for both AcCoA and folate 
using human NAT1 as well as three rodent Nat2 enzymes. The fact that folate 
and DHF support the AcCoA hydrolysis activity makes it a possible endogenous 
activity within a cell. MTX, a folate analog, was not able to support hydrolysis of 
AcCoA to any considerable degree. All these in vitro studies strengthen the 
position that NAT1 can perform an endogenous reaction independent of a 
xenobiotic substrate.   
 
The third chapter suggests that human NAT1, with the use of the ortholog 
rat Nat2 in congenic rats, plays an important role in tumorigenic incidence and 
onset. The strengths of this study are the congenic rat model and the similarity of 
human NAT1 and rat NAT2. The Hein laboratory made the congenic Fischer 344 
rat strains several years ago, and characterized the differences between rapid 
and slow Nat2 congenic rats in previous publications. The rapid and slow NAT2 
congenic F344 rat stains were derived by the same breeding approach, so the 
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genetic background of rapid and slow congenic rats is more than 99.9% similar. 
This very close similarity allows us to compare rapid and slow NAT2 with minimal 
influence of strain differences besides the NAT2 gene. As mentioned in the 
introduction, human NAT1 and rat NAT2 share over 83% amino acid sequence 
homology, with no differences in the active site or the C-terminal tail. The rat 
breast cancer model is a strength because we can measure palpable tumors in 
live animals over time. In theory this study could be conducted on almost any 
form of cancer.  
 
Chemically induced tumors are affected by variable, yet controllable, 
factors like the inducing carcinogen, age of administration, reproductive history, 
and diet. Diet and reproductive history of these rats are the same for both rapid 
and slow congenic rats. Administration of MNU is an approached used for 
several decades to induce mammary tumors in rodents. MNU is a direct acting 
DNA alkylating agent that does not need biotransformation to form DNA adducts. 
It has been shown that sexually immature F344 rats (at 3 weeks of age) are more 
susceptible to mammary carcinogenesis by MNU than mature rats (8 weeks of 
age) [77]. In chapter three, MNU was given at both 3 and 8 weeks of age to 
ensure no possible developmental differences were affecting the results. 
Additionally, rats were treated with another well-studied and utilized carcinogen, 
DMBA, at eight weeks of age. DMBA is a procarcinogen that requires enzymatic 
metabolism to become an active carcinogen. The enzymes that activate DMBA 
have been characterized and do not involve human NAT1/rat NAT2. The use of 
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DMBA shows that tumorigenic differences between rapid and slow NAT2 
congenic rats are not carcinogen related. The study in chapter three is 
strengthened by the different approaches to address the factors that can 
influence chemically induced tumors.  
 
The use of rat embryonic fibroblasts (REFs) to measure the endogenous 
AcCoA levels of rapid and slow congenic strains is necessary in this study. The 
ability to normalize the small amount of detectable AcCoA from HPLC to the 
number of cells is considerably more reliable and reproducible than the extensive 
trials using whole tissue from congenic rats. Whole tissue suffered from 
considerable variability in the data from tissue weights and tissue composition. 
REFs serve to strengthen this study by greatly increasing the reliability of the 
data. 
 
The results in the fourth and fifth chapters use two separate models: a 
partial knockdown and a knockout of NAT1. In both of these model systems, no 
effect on doubling time, number of anchorage-dependent colonies, relative 
cellular invasion ability were found to be non-significantly different between 
wildtype NAT1 activity cells and NAT1 knockout breast cancer cell lines. These 
repetitive findings suggest that NAT1 does not play a role in growth rates, 
anchorage-dependent colony formation, or relative invasion ability for breast 
cancer cells under cell culture conditions. This conclusion differs from that of 
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previous studies by others [11, 12], but is strongly supported by the different 
models and cell lines used within this dissertation.  
 
In the fourth chapter despite a 12-fold overexpression of NAT1 in vitro 
activity, significant (p<0.05) changes in endogenous AcCoA levels, cell doubling 
time, anchorage-dependent growth, anchorage-independent cell growth, or 
relative invasion ability were not observed. In contrast, a previous study using 
HB4a cells reported that NAT1 overexpression resulted in enhanced growth 
properties [8]. The MDA-MB-231 cells used in the present study are a claudin-
low, triple-negative breast cancer cell line whereas the HB4a cell line is derived 
from normal luminal mammary epithelial cells. Thus, the lack of differences 
between scrambled shRNA and NAT1 overexpression MDA-MB-231 cell lines 
may be a result of the cell line utilized. It is also possible that NAT1 has a type of 
threshold effect where increasing NAT1 activity within a cell does not result in a 
significant difference as with knockdown of NAT1 activity. The reduced NAT1 
activity studies could be further strengthened with the inclusion of reestablishing 
the NAT1 activity once it has been completely knocked out. Theoretically the 
difference in anchorage-independent colony formation and the endogenous 
AcCoA level should be restored to that of the parental cell line. The reestablished 
NAT1 activity cell lines are currently being developed and explored within the 




Chapters III, IV, and V all explore the concept presented in chapter II, 
which is that in the presence of folate, NAT1 is able to hydrolyze AcCoA. 
Consistent with this concept, endogenous AcCoA levels in congenic rat 
embryonic fibroblasts, partial NAT1 knockdown cell line, and complete NAT1 
knockout cell lines showed increased AcCoA when the level of NAT1 activity is 
reduced within the cell. The complete NAT1 knockout in MDA-MB-231 cell lines 
elevated endogenous AcCoA levels by 86% to 99%. The complete NAT1 
knockout in MCF7 elevated endogenous AcCoA levels by 45% to 48%. These 
findings are consistent with folate-dependent AcCoA hydrolysis catalyzed by 
NAT1. However the findings do not provide conclusive evidence that the folate-
dependent hydrolysis is the primary or sole mechanism for the elevation of 
AcCoA.  
 
Differences in AcCoA levels could provide an explanation for differences 
in metabolites of fatty acid synthesis and amino acids [131]. The effects of NAT1 
on anchorage-independent cell growth and endogenous AcCoA levels may 
provide insight into why congenic rapid NAT2 rats developed more mammary 
tumors than congenic slow NAT2 rats following administration of mammary 
carcinogens that are not metabolized by rat NAT2 [65].  
 
This dissertation provides evidence that NAT1 influences mammary 
cancer susceptibility and has an endogenous role within a cell. The “complete 
mechanism/role” of NAT1 is still debatable. The mechanism/role discussed within 
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this dissertation focused on NAT1 influence over AcCoA concentrations. Future 
experiments will need to be done to fully understand the ramifications and 







This chapter serves to provide future experiments to expand upon the 
results within this dissertation. The results of this dissertation indicate NAT1 has 
a role in tumorigenesis, anchorage-independent colony formation, and cellular 
AcCoA concentrations. The future directions based off these findings are diverse 
in scope from exploring the role NAT1 might play in DNA damage to exploring 
how altered levels of one of the most important biology compounds, AcCoA, can 
affect cellular functions.  
 
In chapter three, slow NAT2 congenic rats had fewer mammary tumors 
than rapid NAT2 congenic rats following administration carcinogens (MNU and 
DMBA) that are not metabolized by rat NAT2. The difference in tumor incidence 
between the congenic rat strains is hypothesized to be the result of difference in 
DNA damage repair. The first possible experiment is measuring total DNA 
damage in the rapid and slow congenic rats from MNU by alkaline comet assay. 
The other experiment could be measuring the level of H-Ras and K-Ras 
mutations resulting from MNU exposure. While measuring the frequency of 
mutations is not a measure of DNA damage, the mutations are a result of 
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inappropriate DNA repair. These experiments will inform how rat NAT2 activity 
can influence tumorigenic differences.  
 
The comet assay, also known as single-cell gel electrophoresis assay, is a 
simple and sensitive technique for the detection of DNA damage and repair in 
cell lines. A commonly used comet assay is the alkaline comet assay, which is 
performed under high pH (>13). The alkaline comet assay is optimal for 
assessing agents with genotoxic activity [152]. The alkaline comet assay is able 
to detect single-strand breaks, double-strand breaks, and other damage to DNA. 
As discussed in the chapter three, the methylnitrosourea (MNU) mechanism to 
cause cancer is DNA damage resulting from the alkylation of nitrogen and 
oxygen in DNA leading to mutations (figure 3.2). MNU exposure strategy for cell 
lines has been established, and analyzed by alkaline comet assay [153]. The rat 
embryonic fibroblasts (REFs) isolated from the congenic rat model in chapter 
three can be used with an alkaline comet assay. The REFs could be exposed to 
MNU in situ and DNA damage quantified over time. The expected result is that 
slow NAT2 REFs would have reduced levels of DNA damage compared to the 
rapid NAT2 REFs. The parental and NAT1 modified MDA-MB-231 and MCF7 
breast cancer cell lines could also be used with the alkaline comet assay 
following MNU exposure. Preliminary studies have been performed with the 
MDA-MB-231 parental and NAT1 knockout clone cell lines. Currently there is a 
trend of the NAT1 knockout MDA-MB-231 clones having less DNA damage than 
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the parental cells at 24 hours post MNU exposure. Additional experiments are 
needed to confirm that NAT1 knockout serves to reduce DNA damage. 
 
In classical chemical carcinogenesis studies, MNU is shown to commonly 
target the second base of codon 12 of H-Ras and K-Ras to generate a G12D 
mutation [97, 154-158]. This common mutation on codon 12 of H-Ras and K-Ras 
caused by MNU can be used to assess the frequency of mutation between rapid 
and slow NAT2 congenic rats. A study using isolated rapid and slow NAT2 REFs 
to assess the mutation frequency of Ras codon 12 following in situ MNU 
exposure would determine any mutation frequency difference. The expected 
result would be the slow NAT2 REFs have a lower frequency of the mutation 
compared to the rapid NAT2 REFs after MNU exposure. The use of MDA-MB-
231 and MCF7 NAT1 knockout clones could also be used instead of REFs to 
quantify the frequency of codon 12 mutations. MCF7 cell line does not contain 
any mutations at the codon 12 for H-RAS and K-Ras [159]. MDA-MB-231 cell line 
also has no mutations for the codon 12 in H-Ras and K-Ras, however there is a 
known mutation in K-Ras codon 13 (G13D) [159]. The quantification of MNU 
induced mutation at codon 12 can be done with competitive, allele-specific 
TaqMan™ PCR (castPCR) (Life Technologies™, California, USA) [160]. This 
experiment would answer if NAT1 knockout could help cells repair DNA damage 




Additional experiments in relationship to the finding in chapter three range 
from repeat experiments in new animal models to use of new carcinogens. While 
considerable effort was put forward to minimize the differences between rapid 
and slow NAT2 congenic rats, it is still only one animal model. This use of only 
one animal model is a weakness in the study from chapter three. The addition of 
different animal models with altered rodent NAT2 activity, such as mouse and 
hamster, would serve to strengthen tumorigenic study findings [52, 57-59, 161]. 
Another interesting study would be the effect of mammary tumor mastectomies 
on tumor re-occurrence between the rapid and slow NAT2 congenic rats. 
Mammary tumors would be induced with MNU or DBMA, and upon the first 
palpable mass perform a mastectomy to remove the mammary gland to 
subsequently observe if the mastectomy provided increased tumor free periods 
for either the rapid or slow NAT2 congenic rats. The results of this study could 
help guide clinical decisions, when a woman with higher or lower levels of NAT1 
activity is diagnosed with breast cancer. Also since rodent NAT2 is known to 
have wide tissue distribution, conducting chemically induced tumorigenic 
experiments in other tissues should show similar results to the mammary gland 
tumor incidence. There are numerous published chemically induced tumor 
animal models with detailed mechanism information. As with the MNU and 
DMBA, carcinogens should be selected that do not require metabolic activation 




In chapter four and five, anchorage-independent colony formation is 
decreased whenever NAT1 activity is reduced. This raises the question as to 
how NAT1 is able to influence this anchorage-independent colony formation 
finding. The proteins involved for this result are wide ranging, and information is 
lacking to help directly address the mechanistic role of NAT1. To direct future 
research efforts proteomic and acetylomic analysis of MDA-MB-231 parental and 
NAT1 knockout clone cell lines are being conducted. The results of these studies 
will guide future research into proteins that could be involved in the observed 
differences in anchorage-independent colony formation. In addition, proteomics 
and acetylomics will allow for greater understanding of NAT1’s role in cellular 
biology.  
 
The mammalian cell contains more than 8,000 unique acetylation sites on 
proteins [162-164]. Protein acetylation occurs both co-translationally onto the 
N terminal residue of a protein and post-translationally onto the Nε amino group 
of lysine residues. Lysine acetylation is catalyzed by multiple families of lysine 
acetyltransferases (KATs) and reversed by lysine deacetylases (KDACs). AcCoA 
is an essential donor of acetyl groups for acetylation in eukaryotic cells. Reduced 
AcCoA carboxylase (ACC1) expression decreases the amount of AcCoA that 
moves through the fatty acid synthesis pathway, resulting in an increased cellular 
level of AcCoA, globally increased histone acetylation, and altered transcriptional 
regulation [165, 166]. Increased conversion of AcCoA into malonyl-CoA reduces 
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the pool of cellular acetyl-CoA, and globally decreased histone acetylation [166]. 
Although acetylation correlates with the level of AcCoA, it is unclear whether 
AcCoA is rate-limiting for the activity of all KATs. The results from chapter three, 
four, and five show decreased NAT1 activity increases the concentration of 
AcCoA within a cell. This control of AcCoA by NAT1 may mean that NAT1 can 
control the level of protein and histone acetylation. 
 
The growing amount of literature on the importance of protein acetylation 
underscores the importance of understanding how NAT1 influences AcCoA 
concentration, protein post translation modifications, and histone acetylation. The 
use of mass spectrometry can be used to explore how NAT1 activity can affect 
the protein post translation modification landscape, also known as acetylomics. 
Also, NAT1 activity control of cellular AcCoA could provide interesting research in 
spermatogenesis. During the formation of sperm, cells go through a period of 
hyperacetylation. During the hyperacetylation stage, cells could repress NAT1 
expression, so AcCoA levels increase. The NAT1 activity can be determined for 
tissues from different stages of spermatogenesis. The possible repression of 
NAT1 activity should align with the period of hyperacetylation. As discussed in 
chapter four, overexpression NAT1 does not seem to affect the AcCoA 
concentration compared to the parental cell line. The reason for this result is still 
unclear, and could benefit from additional investigations.  
 
As this chapter highlights, there are various experiments that can be 
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pursued as an extension of work presented in this dissertation. The extended 
research should reveal interesting roles for NAT1 in tumorigenesis, anchorage-
independent colony formation, and cellular AcCoA concentrations. The future of 
NAT1 research should prove to be of considerable interest as the massive voids 
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the MDA-MB-231 Triple Negative Breast Cancer Line. Poster 
presentation. Research! Louisville 2017, Louisville, KY 
2. Gardner, J. Q., M. W. Stepp, D. W. Wilkey, M. L.  Merchant, D. W. Hein. 
2017. Identification of the Endogenous Role of Arylamine N-
Acetyltransferase 1 in Cancer Related Cellular Processes through 
Proteomic Analysis. Poster presentation. Research! Louisville 2017, 
Louisville, KY 
3. Furnish, M., M. W. Stepp, M. A. Doll, M. Y. Chang, D. W. Hein. 2017. 
Investigation of arylamine N-acetyltransferase 1 CRISR/Cas9 knockout in 
MDA-MB-231 cell lines via anoikis and invasion assays. Poster 
presentation. Posters at the Capitol, Frankfort, KY 
4. Furnish, M., M. W. Stepp, M. A. Doll, M. Y. Chang, D. W. Hein. 2016. 
Investigation of arylamine N-acetyltransferase 1 CRISR/Cas9 knockout in 
MDA-MB-231 cell lines via anoikis and invasion assays. Oral presentation. 
Proceedings of the Kentucky Academy of Science, Louisville, KY 
5. Stepp, M. W., M. A. Doll, D. W. Hein. 2016. Decreased Human NAT1 or 
Rat NAT2 activity Elevates Cellular Acetyl-coenzyme A Levels. Poster 
presentation. Ohio Valley Society of Toxicology 2016 Annual Meeting, Eli 
Lilly Company, Indianapolis, IN  
6. Stepp, M. W., M. A. Doll, D. W. Hein. 2016. Decreased Human NAT1 or 
Rat NAT2 activity Elevates Cellular Acetyl-coenzyme A Levels. Poster 
presentation. Research! Louisville 2016, Louisville, KY  
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7. Furnish, M., M. W. Stepp, M. A. Doll, M. Y. Chang, D. W. Hein. 2016. 
Investigation Of CRISPR/Cas9 Arylamine N-Acetyltransferase 1 
Knockouts In MDA-MB-231 Cell Lines Via Anoikis And Invasion Assays. 
Poster presentation. Research! Louisville 2016, Louisville, KY 
8. Stepp, M. W., M. A. Doll, D. J. Samuelson, M. G. Sanders, J. C. States, D. 
W. Hein. 2015. Differences Between Rapid and Slow Arylamine N-
acetyltransferase Fischer 344 Congenic Rats in Methylnitrosourea-
induced Mammary Tumors. Oral presentation. Ohio Valley Society of 
Toxicology 2015 Annual Meeting, Northern Kentucky University, Highland 
Heights, Louisville, KY 
9. Stepp, M. W., M. A. Doll, M. G. Sanders, D. W. Hein. 2015. Differences 
between rapid and slow arylamine N-acetyltransferase Fischer 344 
congenic rats in methylnitrosourea-induced breast tumors. Poster 
presentation. Research! Louisville 2015, Louisville, KY 
10. Chang, M. Y., M. W. Stepp, M. A. Doll, D. W. Hein. 2015. Effect of 
Arylamine N-acetyltransferase 1 Knockout by CRISPR/Cas 9 on Doubling 
Time in MDA-MB-231, MCF-7, & ZR-75-1 Breast Cancer Cell Lines. 
Poster presentation. Research! Louisville 2015, Louisville, KY 
11. Stepp, M. W., G. Mamaliga, M. A. Doll, J. C. States, D. W. Hein. 2015. 
Folate-Dependent Hydrolysis of Acetyl-Coenzyme A by Recombinant 
Human and Rodent Arylamine N-Acetyltransferases. Poster presentation. 
Ohio Valley Society of Toxicology 2015 Graduate Student/Postdoc Annual 
Summer Meeting, Cincinnati, OH 
12. Stepp, M. W., G. Mamaliga, M. A. Doll, J. C. States, D. W. Hein. 2015. 
Folate-Dependent Hydrolysis of Acetyl-Coenzyme A by Recombinant 
Human and Rodent Arylamine N-Acetyltransferases. Poster presentation. 
Great Lakes Drug Metabolism and Disposition Group 2015 Meeting, Ann 
Arbor, MI 
13. Stepp, M. W., M. A. Doll, J. C. States, D. W. Hein. 2014. 
Methylnitrosourea tumorigenesis differences between rapid and slow rat 
Nat2 congenic Fischer 344 rats exposed at 8 weeks of age. Poster 
presentation. James Graham Brown Cancer Center Annual Retreat 2014, 
Louisville, KY 
14. Mamaliga, G., M. W. Stepp, M. A. Doll, D. W. Hein. 2014. Folate-
Dependent Acetyl CoA Hydrolysis by Human and Rodent N-
acetyltransferases. Poster presentation. James Graham Brown Cancer 
Center Annual Retreat 2014, Louisville, KY 
15. Stepp, M. W., M. A. Doll, J. C. States, D. W. Hein. 2014. 
Methylnitrosourea tumorigenesis differences between rapid and slow rat 
Nat2 congenic Fischer 344 rats exposed at 8 weeks of age. Poster 
presentation. Research! Louisville 2014, Louisville, KY 
16. Mamaliga, G., M. W. Stepp, M. A. Doll, D. W. Hein. 2014. Folate-
Dependent Acetyl CoA Hydrolysis by Human and Rodent N-
acetyltransferases. Poster presentation. Research! Louisville 2014, 
Louisville, KY 
17. Barve, A. S., M. W. Stepp, M. A. Doll, J. Zhang, G. E. Arteel, S. S. Barve, 
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D. W. Hein. 2014. Hepatocarcinogenic Effects of 4,4 methylenedianaline 
(MDA) and Obesogenic Dietary Components. Poster presentation. 
Research! Louisville 2014, Louisville, KY 
18. Stepp, M. W., M. A. Doll, J. C. States, D. W. Hein. 2014. Incidence of N-
methylnitrosourea–induced breast tumors differ between rapid and slow 
acetylator congenic rat strains. Poster presentation. Great Lakes Drug 
Metabolism and Disposition Group 2014 Meeting, Indianapolis, IN 
19. Stepp, M. W., M. A. Doll, M. G. Sanders, D. W. Hein. 2013. Fischer 344 
rat strains congenic at arylamine N-acetyltransferase differ in breast 
tumorigenesis induced by 1-methyl-1-nitrosourea. Poster presentation. 
James Graham Brown Cancer Center Annual Retreat 2013, Louisville, KY 
20. Stepp, M. W., M. A. Doll, M. G. Sanders, D. W. Hein. 2013. Fischer 344 
rat strains congenic at arylamine N-acetyltransferase differ in breast 
tumorigenesis induced by N-methylnitrosourea. Oral and poster 
presentation. Ohio Valley Society of Toxicology 2013 Annual Meeting, 
Louisville, KY 
 
PRESENTATIONS (20 MOST RECENT) 
1. Poster presentation, 09/2017, Research! Louisville 2017, Louisville, KY 
2. Oral presentation, 06/2017, PhD Dissertation Defense, Louisville, KY 
3. Poster presentation, 3/2017, Society of Toxicology 56th Annual Meeting, 
Baltimore, MD 
4. Poster Presentation, 10/2016, Ohio Valley Society of Toxicology 2016 
Annual Meeting, Eli Lilly Company, Indianapolis, IN 
5. Poster presentation, 10/2016, Research! Louisville 2016, Louisville, KY 
6. Oral Presentation, 6/2016, 7th International Workshop on Arylamine N-
acetyltransferases, Tier, Germany 
7. Oral Presentation, 6/2016, 7th International Workshop on Arylamine N-
acetyltransferases, Trier, Germany 
8. Oral Presentation, 6/2016, Colloquia on Cancer Biology and 
Therapeutics, Louisville, KY 
9. Poster presentation, 3/2016, Society of Toxicology 55th Annual Meeting, 
New Orleans, LA 
10. Oral Presentation, 11/2015, Ohio Valley Society of Toxicology 2015 
Annual Meeting, Northern Kentucky University, Highland Heights, KY 
11. Poster presentation, 10/2015, Research! Louisville 2015, Louisville, KY 
12. Poster presentation, 6/2015, Ohio Valley Society of Toxicology 2015 
Graduate Student/Postdoc Annual Summer Meeting, Cincinnati, OH 
13. Poster presentation, 5/2015, Great Lakes Drug Metabolism and 
Disposition Group 2015 Meeting, Ann Arbor, MI 
14. Poster presentation, 3/2015, Society of Toxicology 54th Annual Meeting, 
San Diego, CA 
15. Poster presentation, 10/2014, James Graham Brown Cancer Center 
Annual Retreat 2014, Louisville, KY,  
16. Poster presentation, 9/2014, Research! Louisville 2014, Louisville, KY 
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17. Oral presentation, 08/2014, Masters Defense/PhD Proposal Defense, 
Louisville, KY 
18. Poster presentation, 5/2014, Great Lakes Drug Metabolism and 
Disposition Group 2014 Meeting, Indianapolis, IN 
19. Poster presentation, 10/2013, James Graham Brown Cancer Center 
Annual Retreat 2013, Louisville, KY 
20. Oral Presentation, 10/2013, Sixth International Workshop on Arylamine 
N-acetyltransferases, Toronto, ON  
 
 
 
 
